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What is New in the 2005 NARMS Report?  
 
 
A New Look to NARMS  
 
NARMS has a new look.  Blue headline boxes differentiate between sections to facilitate navigating the annual 
report.  Boxes in a blue double line border are at the beginning of each section, which consist of the major take 
home points of the NARMS 2005 Annual report.  
 
NARMS gets interactive.  The table of contents, list of tables, list of figures and all referenced tables and figures in 
the text are interactive, allowing quick access to tables and figures. 
 
Antimicrobial Agents of Critical Importance   
 
In May 2007, experts selected by the World Health Organization met in an expert consultation in Copenhagen to 
evaluate critically important antimicrobial agents for human medicine.  The report from this meeting defines two 
criteria for antimicrobial agents important in human medicine:  Criterion 1 is that the antimicrobial agent is the sole 
therapy or one of few alternatives to treat serious human disease.  Criterion 2 is that the antimicrobial agent is 
used to treat diseases caused by organisms that may be transmitted via non-human sources or diseases caused 
by organisms that may acquire resistant genes from non-human sources.  “Critically Important” antimicrobial 
agents are those that meet both criteria.  “Highly Important” antimicrobial agents are those that meet one criteria.  
“Important” antimicrobial agents are those that meet neither criteria one nor two.1  The antimicrobial agents in the 
NARMS annual report tables are ordered using these criteria (Table I). 
 
Antimicrobial Resistance in Humans  
 
A separate list of antimicrobial agents used for susceptibility testing is shown for Campylobacter, instead of an 
overall list showing antimicrobial agents for Campylobacter, Salmonella, Shigella, and E. coli O157 used in 
previous reports.  The new Campylobacter table consists of 10 antimicrobial agents, of which two agents, 
florfenicol and telithromycin, were added in 2005.  Minimum inhibitory concentrations (MICs) are interpreted using 
criteria established by the Clinical and Laboratory Standards Institute (CLSI) when available. For agents tested in 
NARMS for Campylobacter, CLSI breakpoints have only been published for erythromycin, ciprofloxacin, and 
tetracycline.  If CLSI breakpoints are not available, we used breakpoints from the CDC-NARMS counterpart at the 
Food and Drug Administration (FDA) Center for Veterinary Medicine.  
 
An explanation on “how to read a table,” showing the distribution of MICs for antimicrobial agents tested, which 
we refer to as “squashtogram”, has been provided to assist the reader with the different parts of each table 
(Figure 1.01). 
 
Proportional figures are new additions that visually display data from squashtograms for an immediate 
comparative summary of resistance in specific pathogens and serotypes.  These figures are a categorical visual 
aid for the interpretation of MIC values.  For most antimicrobial agents tested, three categories (susceptible, 
intermediate, and resistant) are used to interpret MICs.  The proportion representing each category is shown in a 
horizontal proportional bar chart (Figure 1.02). 
 
 
                                                     
1
World Health Organization.  Critically Important Antimicrobials for Human Medicine: Categorization for the Development of Risk Management 
Strategies to contain Antimicrobial Resistance due to Non-Human Antimicrobial Use.  Report of the second WHO Expert Meeting 









The National Antimicrobial Resistance Monitoring System (NARMS) for Enteric Bacteria is a collaboration among 
the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and U.S. 
Department of Agriculture (USDA).  The primary purpose of NARMS at CDC is to monitor antimicrobial resistance 
among foodborne enteric bacteria isolated from humans.  Other components of the interagency NARMS program 
include surveillance for resistance in human enteric bacterial pathogens isolated from foods, conducted by the 
FDA Center for Veterinary Medicine (http://www.fda.gov/cvm/narms_pg.html), and resistance in human enteric 
pathogens isolated from animals, conducted by the USDA Agricultural Research Services 
(http://www.ars.usda.gov/main/site_main.htm?modecode=66-12-05-08).   
 
Many NARMS activities are conducted within the framework of CDC’s Emerging Infections Program (EIP), 
Epidemiology and Laboratory Capacity (ELC) Program, and the Foodborne Diseases Active Surveillance Network 
(FoodNet).  In addition to surveillance of resistance in enteric pathogens, the NARMS program at CDC also 
includes public health research into the mechanisms of resistance, education efforts to promote prudent use of 
antimicrobial agents, and studies of resistance in commensal organisms. 
 
Before NARMS was established, CDC monitored antimicrobial resistance in Salmonella, Shigella, and 
Campylobacter through periodic surveys of isolates from a panel of sentinel counties. NARMS at CDC began in 
1996 with prospective monitoring of antimicrobial resistance among clinical non-Typhi Salmonella and 
Escherichia coli O157 isolates in 14 sites. In 1997, testing of clinical Campylobacter isolates was initiated in the 
five sites participating in FoodNet. Testing of clinical Salmonella Typhi and Shigella isolates was added in 1999. 
Since 2003, all 50 states have been forwarding a representative sample of non-Typhi Salmonella, Salmonella 
Typhi, Shigella, and E. coli O157 isolates to NARMS for antimicrobial susceptibility testing, and 10 FoodNet states 
have been participating in Campylobacter surveillance. 
 
This annual report includes CDC’s surveillance data for 2005 for clinical non-Typhi Salmonella, Salmonella Typhi, 
Shigella, and E. coli O157 isolates. Resistance trends and comparisons with previous years are included when 
appropriate. Antimicrobial subclasses defined by CLSI are used in data presentation and analysis. CLSI 
subclasses constitute major classifications of antimicrobial agents, e.g., aminoglycosides and cephalosporins. 
 
This report also includes data from the Escherichia coli Resistance Study, which is part of NARMS surveillance on 
commensal bacteria.  Appendix A summarizes the Escherichia coli Resistance Surveillance Pilot Study conducted 
in 2005.  Appendix B provides some examples of how the NARMS MIC distributions of Escherichia coli compare 
with the distributions defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). 
 









In 2005, all 50 states participated in NARMS, representing approximately 296 million persons (Table II). 
Surveillance for antimicrobial resistance included non-Typhi Salmonella, Salmonella Typhi, Shigella, and 
Escherichia coli O157. Campylobacter resistance to antimicrobial agents was monitored in 10 states that also 
participated in the Foodborne Diseases Active Surveillance Network (FoodNet), representing approximately 44.9 
million persons (15.2% of the U.S. population). 
 
 
Clinically Important Antimicrobial Resistance Patterns  
 
In the United States, certain quinolones (e.g., the fluoroquinolone ciprofloxacin) and third-generation 
cephalosporins (e.g., ceftriaxone) are antimicrobial agents commonly used to treat severe Campylobacter and 
Salmonella infections, including Salmonella serotype Typhi, the organism that causes typhoid fever. Nalidixic acid 
is an elementary quinolone; resistance to nalidixic acid correlates with decreased susceptibility to ciprofloxacin 
and possible treatment failure. Ceftiofur is a third-generation cephalosporin used in food animals in the United 
States; resistance to ceftiofur correlates with decreased susceptibility to ceftriaxone. A substantial proportion of 
isolates tested by NARMS in 2005 demonstrated resistance to these clinically important antimicrobial agents, as 
follows: 
• 21.7% (193/890) of Campylobacter isolates were resistant to the fluoroquinolone ciprofloxacin, compared with 
12.9% (28/217) in 1997 (OR=2.2, 95% CI [1.4, 3.4]). 
o 23.5% (23/98) of Campylobacter coli isolates were resistant to ciprofloxacin. 
o 21.5% (170/791) of Campylobacter jejuni isolates were resistant to ciprofloxacin. 
• 2.9% (59/2052) of non-Typhi Salmonella isolates were resistant to the quinolone nalidixic acid, compared with 
0.4% (5/1324) in 1996 (OR=8.1, 95% CI [3.2, 20.5]). 
o Salmonella Enteritidis was the second most common serotype among nalidixic acid-resistant non-
Typhi Salmonella isolates: 36.0% (18/50) of quinolone-resistant isolates were serotype Enteritidis. 
o Nalidixic acid resistance in Salmonella Enteritidis was 4.7% (18/383) in 2005, compared with 
0.9% (3/351) in 1996 (OR 95% CI [1.6, 30.5]). 
• 2.9% (60/2052) of non-Typhi Salmonella isolates were resistant to the third-generation cephalosporin 
ceftiofur, compared with 0.2% (2/1324) in 1996 (OR=24.4, 95% CI [5.9, 100.2]). 
o Salmonella Newport was the most common serotype among ceftiofur-resistant non-Typhi 
Salmonella isolates: 43.3% (26/60) of ceftiofur-resistant isolates were serotype Newport. 
• 48.4% (154/318) of Salmonella Typhi isolates were resistant to the quinolone nalidixic acid, compared with 





Multidrug resistance is described in NARMS by the number of antimicrobial subclasses or specific coresistant 
phenotypes. Antimicrobial subclasses are used as defined by the Clinical and Laboratory Standards Institute 
(CLSI) (Table III).  Multidrug resistance by the number of antimicrobial subclasses is defined as resistance to two 
or more CLSI subclasses. For non-Typhi Salmonella,  common multidrug-resistant phenotypes in 2005 include 
resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline 
(ACSSuT) and resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, 
tetracycline, amoxicillin-clavulanic acid, and ceftiofur, and decreased susceptibility to ceftriaxone (minimum 
inhibitory concentration ≥2 μg/mL) (MDR-AmpC). 
 
• 14.8% (304/2052) of non-Typhi Salmonella isolates were resistant to two or more CLSI subclasses, and 7.6% 
(156/2052) were resistant to five or more CLSI subclasses. 
o 15.0% (31/207) of Salmonella Newport isolates were resistant to two or more CLSI subclasses, 
and 12.6% (26/207) were resistant to five or more CLSI subclasses. 
o 33.2% (145/437) of Salmonella Typhimurium isolates were resistant to two or more CLSI 
subclasses, and 23.6% (103/437) were resistant to five or more CLSI subclasses. 
14 
o 3.7% (14/383) of Salmonella Enteritidis isolates were resistant to two or more CLSI subclasses, 
and 0.5% (2/383) were resistant to five or more CLSI subclasses. 
 
• 6.9% (141/2052) of non-Typhi Salmonella isolates had the  ACSSuT resistance pattern, compared with 8.8% 
(116/1324) in 1996 (Table ll). 
o 22.2% (97/437) of Salmonella Typhimurium isolates were ACSSuT, compared with 33.7% 
(103/306) in 1996(OR=0.6, 95% CI [0.4, 0.8]). 
o 12.6% (26/207) of Salmonella Newport isolates were ACSSuT, compared with 5.9% (3/51) in 
1996. 
• 2.0% (41/2052) of non-Typhi Salmonella isolates had the MDR-AmpC phenotype (Table III). These isolates 
consisted of five different serotypes. In 1996, MDR-AmpC was not detected in any serotype. 
o 12.6% (26/207) of Salmonella Newport isolates were MDR-AmpC, compared with none (0/51) in 
1996 (95% CI [1.8, infinity]). 
o 1.8% (8/437) of Salmonella Typhimurium isolates were MDR-AmpC.
 
 
Table I:  World Health Organization’s categorization of antimicrobials of critical importance to human 
medicine1 
Critical  
Importance CLSI Subclass Antimicrobial Agent 
Categorization of 
Antimicrobials 
Amikacin Critically important2 
Gentamicin Critically important Aminoglycosides 
Streptomycin Critically important 




acid Critically important 
Cephalosporins 
 (3rd generation)  Ceftriaxone
5 Critically important 
Ketolides Telithromycin Critically important 
Azithromycin Critically important Macrolides Erythromycin Critically important 
Ciprofloxacin Critically important 
I 
Quinolones Nalidixic acid Critically important 
Aminoglycosides Kanamycin Highly important3 
Cephalosporin 
(1st generation) Cephalothin Highly important 
Cephamycins Cefoxitin Highly important 
Folate pathway inhibitors Trimethoprim- Sulfamethoxazole Highly important 
Phenicols Chloramphenicol6 Highly important 
Sulfamethoxazole Highly important Sulfonamides¶ Sulfisoxazole Highly important 
II 
Tetracyclines Tetracycline Highly important 
III Lincosamides Clindamycin Important4 
 
1World Health Organization.  Critically Important Antimicrobials for Human Medicine: Categorization for the Development of Risk Management 
Strategies to contain Antimicrobial Resistance due to Non-Human Antimicrobial Use.  Report of the second WHO Expert Meeting 
Copenhagen, 29-31 May 2007. 
2Both Criteria 1 and 2 met 
3Either criteria 1 or 2 met but not both 
4Neither criteria 1 or 2 met 
Criteria 1 – the antimicrobial is the sole or one of few agents available for treatment of serious infections 
Criteria 2 – Agent used to treat diseases caused by bacteria that may be transmitted from non-human sources to humans. 
5Ceftiofur, a third-generation cephalosporin used in veterinary medicine is included in the panel of drugs. 
6 Florfenicol, a phenicol used in veterinary medicine has replaced chloramphenicol in 2005.
Table II: Population size and number of isolates received and tested, by site, NARMS, 2005 
15 
N (%) N (%) N (%) N (%) N (%)
Alabama 4,539,611 46 (2.2%) 2 (0.6%) 13 (3.3%) 2 (1.0%) N/A
Alaska 669,411 5 (0.2%) 1 (0.3%) 1 (0.3%) 1 (0.5%) N/A
Arizona 5,952,083 37 (1.8%) 4 (1.3%) 17 (4.3%) 2 (1.0%) N/A
Arkansas 2,772,152 39 (1.9%) 0 (0.0%) 0 (0.0%) 6 (3.1%) N/A
California‡ 32,143,253 143 (7.0%) 37 (11.6%) 2 (0.5%) 4 (2.1%) 71 (8.0%)
Colorado 4,673,724 30 (1.5%) 7 (2.2%) 2 (0.5%) 4 (2.1%) 110 (12.4%)
Connecticut 3,486,490 31 (1.5%) 8 (2.5%) 3 (0.8%) 2 (1.0%) 55 (6.2%)
Delaware 840,558 8 (0.4%) 3 (0.9%) 1 (0.3%) 2 (1.0%) N/A
District of Columbia 582,049 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) N/A
Florida 17,736,027 52 (2.5%) 12 (3.8%) 0 (0.0%) 0 (0.0%) N/A
Georgia 9,107,719 108 (5.3%) 8 (2.5%) 26 (6.6%) 27 (13.9%) 163 (18.3%)
Hawaii 1,267,581 16 (0.8%) 11 (3.5%) 1 (0.3%) 1 (0.5%) N/A
Houston, Texas§ 2,117,937 28 (1.4%) 6 (1.9%) 1 (0.3%) 0 (0.0%) N/A
Idaho 1,425,894 8 (0.4%) 0 (0.0%) 1 (0.3%) 1 (0.5%) N/A
Illinois 12,719,550 92 (4.5%) 23 (7.2%) 21 (5.3%) 6 (3.1%) N/A
Indiana 6,257,121 35 (1.7%) 3 (0.9%) 2 (0.5%) 3 (1.5%) N/A
Iowa 2,955,587 18 (0.9%) 2 (0.6%) 3 (0.8%) 3 (1.5%) N/A
Kansas 2,741,665 15 (0.7%) 0 (0.0%) 8 (2.0%) 2 (1.0%) N/A
Kentucky 4,171,016 24 (1.2%) 4 (1.3%) 14 (3.5%) 1 (0.5%) N/A
Los Angeles¶ 3,847,059 68 (3.3%) 23 (7.2%) 5 (1.3%) 0 (0.0%) N/A
Louisiana 4,495,670 40 (1.9%) 0 (0.0%) 1 (0.3%) 0 (0.0%) N/A
Maine 1,312,222 9 (0.4%) 2 (0.6%) 1 (0.3%) 2 (1.0%) N/A
Maryland 5,573,163 30 (1.5%) 11 (3.5%) 11 (2.8%) 25 (12.9%) 64 (7.2%)
Massachusetts 6,429,137 57 (2.8%) 14 (4.4%) 10 (2.5%) 2 (1.0%) N/A
Michigan 10,107,940 42 (2.0%) 5 (1.6%) 7 (1.8%) 3 (1.5%) N/A
Minnesota 5,113,824 33 (1.6%) 6 (1.9%) 4 (1.0%) 5 (2.6%) 146 (16.4%)
Mississippi 2,900,456 38 (1.9%) 2 (0.6%) 2 (0.5%) 0 (0.0%) N/A
Missouri 5,787,885 59 (2.9%) 1 (0.3%) 44 (11.1%) 7 (3.6%) N/A
Montana 935,784 6 (0.3%) 0 (0.0%) 1 (0.3%) 1 (0.5%) N/A
Nebraska 1,754,042 13 (0.6%) 0 (0.0%) 9 (2.3%) 4 (2.1%) N/A
Nevada 2,408,948 14 (0.7%) 1 (0.3%) 4 (1.0%) 4 (2.1%) N/A
New Hampshire 1,303,112 8 (0.4%) 0 (0.0%) 1 (0.3%) 1 (0.5%) N/A
New Jersey 8,657,445 49 (2.4%) 20 (6.3%) 10 (2.5%) 12 (6.2%) N/A
New Mexico 1,916,331 12 (0.6%) 1 (0.3%) 8 (2.0%) 1 (0.5%) 40 (4.5%)
New York4 11,048,706 91 (4.4%) 8 (2.5%) 9 (2.3%) 6 (3.1%) 116 (13.0%)
New York City** 8,213,839 76 (3.7%) 30 (9.4%) 20 (5.1%) 5 (2.6%) N/A
North Carolina 8,679,089 90 (4.4%) 5 (1.6%) 6 (1.5%) 2 (1.0%) N/A
North Dakota 635,938 5 (0.2%) 0 (0.0%) 5 (1.3%) 1 (0.5%) N/A
Ohio 11,459,776 65 (3.2%) 1 (0.3%) 5 (1.3%) 7 (3.6%) N/A
Oklahoma 3,535,926 23 (1.1%) 1 (0.3%) 31 (7.8%) 3 (1.5%) N/A
Oregon 3,629,959 23 (1.1%) 4 (1.3%) 5 (1.3%) 5 (2.6%) 74 (8.3%)
Pennsylvania 12,367,276 89 (4.3%) 6 (1.9%) 6 (1.5%) 4 (2.1%) N/A
Rhode Island 1,066,721 7 (0.3%) 1 (0.3%) 1 (0.3%) 0 (0.0%) N/A
South Carolina 4,254,989 32 (1.6%) 0 (0.0%) 3 (0.8%) 1 (0.5%) N/A
South Dakota 780,046 8 (0.4%) 0 (0.0%) 3 (0.8%) 2 (1.0%) N/A
Tennessee 5,989,309 34 (1.7%) 2 (0.6%) 25 (6.3%) 2 (1.0%) 51 (5.7%)
Texas†† 20,726,062 55 (2.7%) 18 (5.7%) 14 (3.5%) 0 (0.0%) N/A
Utah 2,505,013 16 (0.8%) 1 (0.3%) 2 (0.5%) 3 (1.5%) N/A
Vermont 619,736 4 (0.2%) 0 (0.0%) 0 (0.0%) 1 (0.5%) N/A
Virginia 7,557,588 65 (3.2%) 16 (5.0%) 4 (1.0%) 3 (1.5%) N/A
Washington 6,270,838 45 (2.2%) 4 (1.3%) 11 (2.8%) 8 (4.1%) N/A
West Virginia 1,805,626 54 (2.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) N/A
Wisconsin 5,540,473 48 (2.3%) 4 (1.3%) 11 (2.8%) 5 (2.6%) N/A
Wyoming 506,541 9 (0.4%) 0 (0.0%) 1 (0.3%) 2 (1.0%) N/A
Total 295,895,897 2052 (100.0%) 318 (100.0%) 396 (100.0%) 194 (100.0%) 890 (100.0%)
* US Census Bureau, 2005
† Campylobacter  isolates are submitted only from FoodNet sites; total population size of FoodNet sites was 44,531,182
‡ Excluding Los Angeles County
§ Houston City
¶ Los Angeles County
4 Excluding New York City
** Five burroughs of New York City (Bronx, Brooklyn, Manhattan, Queens, Staten Island)
†† Excluding Houston, Texas








Table III: Summary of trend analysis of the proportion of specific resistance phenotypes among 
Campylobacter, non-Typhi Salmonella, and Salmonella Typhi isolates, 2005 
Resistance Phenotype Reference Year Odds Ratio [95% CI]* 
Ciprofloxacin resistance in Campylobacter 1997 2.2 [1.4–3.4] 
Nalidixic acid resistance in non-Typhi 
Salmonella 1996 8.1 [3.2–20.5] 
Nalidixic acid resistance in Salmonella 
Enteritidis 1996 –
† [1.6–30.5]† 
Ceftiofur resistance in non-Typhi 
Salmonella 1996 24.4 [5.9–100.2] 
Nalidixic acid resistance in Salmonella 
Typhi 1999 4.0 [2.5–6.3] 
ACSSuT resistance in Salmonella 
Typhimurium‡ 1996 0.6 [0.4–0.8] 




* For logistic regression models that adjusted for site, odds ratios (ORs) (2005 vs. reference year) and 95% confidence 
intervals (CIs) were calculated using unconditional maximum likelihood estimation. 
† Model included only year. In the analysis, the maximum likelihood estimate of the OR did not exist; only the 95% CIs, 
calculated using unconditional exact methods, are reported. 
‡ Resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline. 
§ Resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, amoxicillin-





Surveillance and Laboratory Testing Methods  
 
 
Surveillance Sites and Isolate Submissions  
 
In 2005, NARMS conducted nationwide surveillance among the population of approximately 296 million persons 
(2005 U.S. Census Bureau estimates). Public health laboratories systematically selected every 20th non-Typhi 
Salmonella (i.e., all Salmonella serotypes except serotype Typhi), Shigella, and Escherichia coli O157 isolate and 
every Salmonella Typhi isolate received at their laboratories and forwarded these isolates to CDC for 
antimicrobial susceptibility testing. 
 
In 2005, a new scheme for Campylobacter isolate submission was initiated.  Public health laboratories of the 10 
state health departments that participated in CDC’s Foodborne Diseases Active Surveillance Network (FoodNet) 
forwarded a representative sample of Campylobacter isolates to CDC for susceptibility testing. The FoodNet sites, 
representing approximately 45 million persons (2005 U.S. Census Bureau estimates), comprised California, 
Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and Tennessee.  There 
were three methods of selecting a representative sample of isolates for submission to CDC:  all isolates received 
by Georgia, Maryland, New Mexico, Oregon, and Tennessee; every other isolate from California, Colorado, 
Connecticut, and New York; and every fifth isolate from Minnesota. From 1997 to 2004, one Campylobacter 
isolate each week from participating FoodNet sites was submitted to NARMS.  This submission scheme was 
described in the 2004 report4. 
 
 
Testing of Salmonella, Shigella, and Escherichia coli O157  
  
Antimicrobial Susceptibility Testing 
 
Salmonella, Shigella, and E. coli O157 isolates were tested using broth microdilution (Sensititre
®
, Trek 
Diagnostics, Westlake, OH) to determine the minimum inhibitory concentration (MIC) for each of 15 antimicrobial 
agents: amikacin, ampicillin, amoxicillin-clavulanic acid, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, 
ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-
sulfamethoxazole (Table IV). Before 2004, sulfamethoxazole was used instead of sulfisoxazole to represent the 
sulfonamides. Interpretive criteria defined by the Clinical and Laboratory Standards Institute (CLSI) were used 
when available1. The resistance breakpoint for amikacin, according to CLSI guidelines, is ≥64 μg/mL. In 2002 and 
2003, a truncated broth microdilution series was used for amikacin testing (0.5-4 µg/mL).  For isolates that grew in 
all amikacin dilutions on the Sensititre
   
panel (MIC>4 μg/mL), E-Test (AB BIODISK, Solna, Sweden) was 
performed to determine amikacin MIC. The amikacin E-Test strip range of dilutions was 0.016-256 μg/mL. Since 
2004, amikacin had a full range of dilutions (0.5-64 µg/mL ) on the Sensititre panel (CMV1AGNF). 
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Table IV: Antimicrobial agents used for susceptibility testing for Salmonella, Shigella, and Escherichia coli 
O157 isolates, NARMS, 2005 
Breakpoints 
CLSI Subclass Antimicrobial Agent 
Antimicrobial Agent 
Concentration 
Range (μg/mL) Susceptible Intermediate Resistant 
Amikacin 0.5–64 ≤16 32 ≥64 
Gentamicin 0.25–16 ≤4 8 ≥16 
Kanamycin 8–64 ≤16 32 ≥64 
Aminoglycosides 
Streptomycin 32–64 ≤32  ≥64 
Aminopenicillins Ampicillin 1–32 ≤8 16 ≥32 
β-Lactamase inhibitor 
combinations Amoxicillin-Clavulanic acid 1/0.5–32/16 ≤8 / ≤4 16/8 ≥32 / ≥16 
Cephalosporin 
(1st generation) Cephalothin
‡ 2–32 ≤8 16 ≥32 
Ceftiofur§ 0.12–8 ≤2 4 ≥8 Cephalosporins 
 (3rd generation) Ceftriaxone 0.25–64 ≤8 16–32 ≥64 
Cephamycins Cefoxitin 0.5–32 ≤8 16 ≥32 
Folate pathway inhibitors Trimethoprim- Sulfamethoxazole 0.12/2.4–4/76 ≤2 / ≤38  ≥4 / ≥76 
Phenicols Chloramphenicol 2–32 ≤8 16 ≥32 
Ciprofloxacin 0.015–4 ≤1 2 ≥4 
Quinolones 
Nalidixic acid 0.5–32 ≤16  ≥32 
Sulfamethoxazole 16–512 ≤256  ≥512 
Sulfonamides¶ 
Sulfisoxazole 16–256 ≤256  ≥512 
Tetracyclines Tetracycline 4–32 ≤4 8 ≥16 
 
‡ Cephalothin was not tested in 2004 and 2005 but was tested in earlier years for Salmonella, Shigella, and E. coli O157. 
§ No CLSI breakpoints; resistance breakpoint used in NARMS is 8 µg/mL. 




Additional Testing of Salmonella strains 
 
Cephalosporin Retesting of isolates from 1996-1998 
 
Review of Salmonella isolates tested in NARMS during 1996–1998 gave conflicting cephalosporin susceptibility 
results. In particular, some isolates previously reported in NARMS as ceftiofur-resistant exhibited a low 
ceftriaxone MIC and, in some cases, did not exhibit an elevated MIC to other β-lactams. Because these findings 
suggested that some previously reported results were inaccurate, we retested, using the 2003 NARMS Sensititre® 
plate, isolates of Salmonella tested in NARMS during 1996–1998 that exhibited an MIC ≥2 μg/mL to ceftiofur or 




To distinguish serotypes Paratyphi B and Paratyphi B var L(+) tartrate+ (formerly Salmonella Java), tartrate 
testing was performed at CDC on all Salmonella Paratyphi B isolates isolated from 1996 to 2005 for which the 
tartrate result was not reported or was reported to be negative. Jordan's tartrate test was used to determine 
tartrate fermentation, and Kauffman's tartrate test subsequently was performed on isolates negative for tartrate 
fermentation by Jordan's tartrate test. Isolates negative for tartrate fermentation by both assays were categorized 
as serotype Paratyphi B. Isolates that were positive for tartrate fermentation by either assay were categorized as 
serotype Paratyphi B var L(+) tartrate+. Confirmation of other biochemical reactions or somatic and flagellar 
antigens was not performed at CDC.  
Salmonella serotype was accepted as reported with few exceptions. Because of increased submissions of 
Salmonella Typhimurium isolates lacking the second phase flagellar antigen (i.e., Salmonella I 4,[5],12:i:-), reports 
of such isolates tested in NARMS during 1996–2005 were reviewed, and isolates identified as serogroup B that 
exhibited first-phase flagellar antigen “I” but lacked a second phase are referred to in this report as Salmonella I 
4,[5],12:i:- (monophasic Typhimurium).  Serogroup B isolates for which the first-phase flagellar antigen was not 
reported were not included in this category because they could be one of several other serogroup B serotypes.  






Testing of Campylobacter 
 
Changes in testing methods in 2005 
 
In 2005, there were two major changes in the methodology for Campylobacter.  A scheme for selecting a 
representative sample of Campylobacter isolates for submission by FoodNet sites was initiated in 2005, which 
changed from a scheme that selected one Campylobacter isolate each week for submission during 1997 to 2004. 
In 2005, Campylobacter isolates were susceptibility tested using Sensititre; isolates were tested by E-test from 
1997 to 2004.  In addition, florfenicol replaced chloramphenicol and telithromycin was added to the NARMS panel 
of agents tested in 2005. 
 
 
Identification/Speciation and Antimicrobial Susceptibility Testing 
 
In 2005, isolates were confirmed as Campylobacter by dark-field microscopy, catalase, and oxidase test. 
Identification of C. jejuni was performed using the hippurate hydrolysis test. Hippurate-positive isolates 
were identified as C. jejuni. Hippurate-negative isolates were identified by polymerase chain reaction 
(PCR) as C. jejuni using a hippuricase gene-based PCR assay2, or as C. coli using a C. coli-specific ceuE 
PCR3.
 
Isolates determined to be neither C. jejuni nor C. coli were identified by alternative PCR methods4. 
The same methodology was used during 1997–2003.
   
In 2004, putative Campylobacter isolates were identified as Campylobacter jejuni or Campylobacter coli 
by PCR using species-specific BAX®
 
primers according to the manufacturer's instructions (DuPont 
Qualicon, Wilmington, DE). Isolates not identified as C. jejuni or C. coli were further characterized in 
conjunction with the CDC Campylobacter Reference Laboratory.  
In 2005, the broth microdilution methodology (Sensititre
®
,Trek Diagnostics, Westlake, OH) was used to determine 
the MICs for nine antimicrobial agents: azithromycin, ciprofloxacin, clindamycin, erythromycin, florfenicol, 
gentamicin, nalidixic acid, telithromycin, and tetracycline (Table V). Florfenicol replaced chloramphenicol in the 
NARMS panel to represent the phenicol antimicrobial subclass.  Similar to the 2004 report, CLSI interpretive 
criteria for erythromycin, ciprofloxacin, and tetracycline (published in 2006) and revised NARMS criteria for 
azithromycin were used for all years in this report5,6. 
 
In annual reports published before 2004, these CLSI 
interpretive criteria were not available, and NARMS used resistance breakpoints for azithromycin and 
erythromycin that were lower than the new and revised breakpoints.
 
 In addition, revised NARMS interpretive 
criteria, adopted from the FDA arm of NARMS, have been used for clindamycin, gentamicin, and nalidixic acid 




Table V: Antimicrobial agents used for susceptibility testing of Campylobacter isolates, NARMS, 1997-
2005 
Breakpoints 
CLSI Subclass Antimicrobial Agent 
Antimicrobial Agent 
Concentration Range (µg/mL) 
Susceptible Intermediate Resistant 
Aminoglycosides Gentamicin 0.12-32 0.016–256* ≤2 4 ≥8 
Ketolides Telithromycin† 0.015-8 ≤4 8 ≥16 
Lincosamides Clindamycin 0.03-16 0.016–256* ≤2 4 ≥8 
Azithromycin 0.015-64 0.016–256* ≤2 4 ≥8 Macrolides 
Erythromycin 0.03-64 0.016–256* ≤8 16 ≥32 
Chloramphenicol‡ 0.016-256* ≤8 16 ≥32 
Phenicols 
Florfenicol§ 0.03-64 ≤4 N/A N/A 
Ciprofloxacin 0.015–64 0.002–32* ≤1 2 ≥4 Quinolones 
Nalidixic acid 4-64 0.016–256* ≤16 32 ≥64 
Tetracyclines Tetracycline 0.06-64 0.016–256* ≤4 8 ≥16 
 
*E-test dilution range used from 1997-2004. 
†Telithromycin added to NARMS panel in 2005. 
‡Chloramphenicol, tested from 1997-2004, was replaced by florfenicol in 2005.  






Known mechanisms of quinolone resistance in Campylobacter are expected to confer equivalent susceptibilities 
to nalidixic acid and ciprofloxacin. Similarly, known mechanisms of macrolide resistance are expected to confer 
equivalent susceptibilities to erythromycin and azithromycin. Confirmatory testing of isolates with conflicting 
results was performed by broth microdilution methods (Sensititre
®
, Trek Diagnostics, Westlake, OH). Totals 




For all pathogens, MICs were categorized as resistant, intermediately susceptible (if applicable), or susceptible. 
Analysis was restricted to one isolate (per genus under surveillance) per patient. Where established, CLSI 
interpretive criteria were used; ceftiofur resistance was defined as MIC ≥8 μg/mL (Table IV). The 95% confidence 
intervals (CI) for the percentage of resistant isolates are included in the MIC distribution tables. The 95% CI was 
calculated using the Clopper-Pearson exact method7.
 
Multidrug resistance by CLSI antimicrobial subclass was 
defined as resistance to two or more subclasses.  
When describing results for several years, multidrug resistance for Salmonella and E. coli O157 isolates was 
limited to the nine CLSI subclasses tested in all years from 1996 through 2005 represented by 13 agents: 
amoxicillin-clavulanic acid, ampicillin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, 
kanamycin, nalidixic acid, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, and trimethoprim-
sulfamethoxazole. For Salmonella serotype Typhi and Shigella, results for several years included the nine CLSI 
subclasses tested in all years from 1999 through 2005 represented by 14 agents (13 antimicrobial agents 
mentioned above and amikacin). Similarly, when describing multidrug resistance for several years for 
Campylobacter isolates, multidrug resistance was limited to the five CLSI subclasses tested in all years from 
1997 through 2004, represented by ciprofloxacin, chloramphenicol/florfenicol, clindamycin, erythromycin, 





Logistic regression was performed to compare the change in antimicrobial resistance among Salmonella and 
Campylobacter isolates tested in NARMS during 2005 with that of previous years for the following: 
1. Non-Typhi Salmonella: resistance to nalidixic acid, resistance to ceftiofur, resistance to one or more CLSI 
subclasses. 
2. Salmonella Typhimurium: resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, 
and tetracycline (ACSSuT). 
3. Salmonella Enteritidis: resistance to nalidixic acid. 
4. Salmonella Newport: resistance to at least ACSSuT, amoxicillin-clavulanic acid, and ceftiofur, with decreased 
susceptibility to ceftriaxone (MDR-AmpC). 
5. Salmonella Typhi: resistance to nalidixic acid. 
6. Campylobacter species: resistance to ciprofloxacin. 
7. Campylobacter jejuni: resistance to ciprofloxacin. 
 
The final regression models for non-Typhi Salmonella, and final models for serotypes Typhimurium and Typhi, 
adjusted for site using the nine Public Health Service geographic regions described in the Public Health 
Laboratory Information System (PHLIS [http://www.cdc.gov/ncidod/dbmd/phlisdata/]) based on the patient’s state 
of residence. The PHLIS regions are East North Central, East South Central, Mid-Atlantic, Mountain, New 
England, Pacific, South Atlantic, West North Central, and West South Central. For all regression models that 
adjusted for site, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using unconditional 
maximum likelihood estimation. In the final regression models for serotypes Enteritidis and Newport, which 
included only year and used unconditional exact methods, the maximum likelihood estimate of the OR did not 
exist; only the 95% CIs are reported.  For Campylobacter, the final regression models adjusted for site using 
patient’s state of residence. The adequacy of model fit was assessed in several ways. The significance of the 
main effect of year was assessed using the likelihood ratio test. The likelihood ratio test was also used to test for 
significance of interaction between site and year, although the power of the test to detect a single site-specific 
interaction was low. The Hosmer and Lemeshow goodness-of-fit test also was used8. Finally, residual analysis 
was performed to examine the influence of individual observations. Odds ratios that did not include 1.0 in the 95% 
CI were reported as significant.
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Results for 2005   
 
 
1. Non-Typhi Salmonella  
 
In non-Typhi Salmonella, an increase in resistance to two clinically important subclasses, quinolones (represented 
by nalidixic acid) and third-generation cephalosporins (represented by ceftiofur), was observed from 1996 to 




In 2005, CDC received 2090 non-Typhi Salmonella isolates, of which 2052 (98.2%) were viable and tested for 
antimicrobial susceptibility (Table II). 
 
Fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins (e.g., ceftriaxone) are commonly used 
to treat severe Salmonella infections. Nalidixic acid is an elementary quinolone; resistance to nalidixic acid 
correlates with decreased susceptibility to ciprofloxacin and possible treatment failure. Ceftiofur is a third-
generation cephalosporin used in food animals in the United States; resistance to ceftiofur correlates with 
decreased susceptibility to ceftriaxone. In 2005, the prevalence of resistance among non-Typhi Salmonella 
isolates was 2.4% for quinolones (represented by nalidixic acid) and 2.9% for third-generation cephalosporins 
(represented by ceftiofur) (Table 1.01). 
 
The antimicrobial agents with the highest prevalence of resistance were tetracycline (13.7%), followed by 
sulfisoxazole (12.5%), ampicillin (11.3%), and streptomycin (11.0%).  
 
The prevalence of nalidixic acid resistance increased from 0.4% (5/1324) in 1996 to 2.4% (50/2052) in 2005 
(Table 1.02), a statistically significant increase (OR=8.1, 95% CI [3.2, 20.5]). The prevalence of ceftiofur 
resistance increased from 0.2% (2/1324) in 1996 to 2.9% (60/2052) in 2005, a statistically significant increase 
(OR=24.4, 95% CI [5.9, 100.2]).  The proportion of resistance to most of the agents tested in 2005 was lower than 
in 2004, including ampicillin, amoxicillin-clavulanic acid, ceftiofur, cefoxitin, chloramphenicol, tetracycline, and 
streptomycin.  
 
Of the 2052 non-Typhi Salmonella isolated in 2005, 80.6% (1654) showed no resistance to the drugs tested, a 
slight increase from the 79.6% in 2004 (Table 1.03). In 2005, 398 (19.4%) were resistant to one or more CLSI 
subclass, 304 (14.8%) to two or more subclasses, 247 (12.0%) to three or more subclasses, 186 (9.1%) to four or 
more subclasses, and 156 (7.6%) to five or more subclasses.  There was a statistically significant decline in 
resistance to one or more subclass from 33.8% in 1996 to 19.4% in 2005 (OR=0.6, 95% CI [0.5, 0.7]) (Table 
1.04).  
 
In 2005, resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and 
tetracycline (ACSSuT) was among the most common multidrug-resistant phenotype (6.9%) among non-Typhi 
Salmonella isolates, but was lower than in 2004 (7.1%), and 1996 (8.8%).  Another common multidrug-resistant 
phenotype among non-Typhi Salmonella isolates was to at least ACSSuT, amoxicillin-clavulanic acid,, and 
ceftiofur, and decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL); this pattern is called MDR-AmpC and  2.0% 
of isolates had this pattern. The prevalence of MDR-AmpC increased from 0% (0/1324) in 1996 to 2.0% (41/2052) 
in 2005.  Seven (0.3%) isolates were resistant to nalidixic acid and ceftiofur (Table 1.03); this pattern was first 
detected in 1997. 
 
In 2005, serotypes were identified for a higher proportion of isolates in NARMS (98.9%) than in the Public Health 
Laboratory Information System (PHLIS) (92.1%) (Table 1.04). The 20 most common serotypes accounted for 
82.5% of isolates in NARMS and 77.2% in PHLIS.  The same five most common serotypes were reported in 
NARMS and PHILIS, which accounted for 59.9% of isolates in NARMS and 56.5% in PHLIS. In NARMS; 1.1% of 
isolates were not completely serotyped in 2005, which was a decline compared with 4.2% in 2004. 
 













%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.13 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.3] 13.3 69.5 15.4 1.7 0.1 0.0
Gentamicin 0.3 2.1 [1.6–2.9] 70.4 25.7 1.3 0.0 0.0 0.3 1.1 1.0
Streptomycin NA 11.0 [9.6–12.4] 89.0 5.9 5.0
Aminopenicillins Ampicillin 0.0 11.3 [10.0–12.8] 76.0 11.9 0.6 0.2 0.1 11.2
β-lactamase 
inhibitor 
Amoxicillin-clavulanic acid 5.1 3.2 [2.5–4.0] 85.2 2.9 0.8 2.8 5.1 1.0 2.1
Ceftiofur 0.2 2.9 [2.2–3.7] 0.5 0.9 58.2 36.5 0.7 0.2 0.1 2.8
Ceftriaxone 2.5 0.1 [0.0–0.4] 97.0 0.1 0.0 0.2 1.3 1.2 0.0 0.1
Ciprofloxacin 0.0 0.0 [0.0–0.3] 96.2 1.0 0.3 1.1 0.6 0.8 0.0 0.0
Nalidixic Acid NA 2.4 [1.8–3.2] 0.1 0.5 31.5 63.8 1.2 0.4 2.4
Aminoglycosides Kanamycin 0.1 3.4 [2.7–4.3] 96.4 0.0 0.1 0.2 3.2
Cephamycins Cefoxitin 0.0 3.0 [2.3–3.9] 0.4 35.9 47.2 12.3 1.1 0.0 0.7 2.3
Folate pathway 
inhibitors
Trimethoprim-sulfamethoxazole NA 1.7 [1.2–2.3] 91.2 6.7 0.3 0.0 1.7
Phenicols Chloramphenicol 0.5 7.7 [6.6–9.0] 2.0 64.6 25.1 0.5 0.1 7.6
Sulfonamides Sulfamethoxazole/Sulf isoxazole NA 12.5 [11.1–14.0] 23.4 48.7 14.6 0.7 0.1 12.5
Tetracyclines Tetracycline 0.1 13.7 [12.3–15.3] 86.2 0.1 1.4 4.4 8.0
Percent of all isolates with MIC (µg/mL)§
Aminoglycosides













95% confidence interval 
for percent resistant
Sum of percents = 
% susceptible
MIC value
Sum of percents = 
% intermediate
Sum of percents = 
% resistant
Single line is upper limit of 
susceptibility / lower limit of 
intermediate resistance
Double line is upper limit of 
intermediate resistance / 
lower limit of full resistance 
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Figure 1.02: Proportional chart, a categorical graph of a squashtogram 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.1 [0.0–0.3] 13.7 69.1 15.3 1.6 0.1 0.1
Gentamicin 0.3 2.1 [1.6–2.9] 70.5 25.6 1.3 0.0 0.0 0.3 1.1 1.0
Streptomycin NA 11.0 [9.6–12.4] 89.0 5.9 5.0
Aminopenicillins Ampicillin 0.0 11.3 [10.0–12.7] 75.6 12.3 0.6 0.2 0.1 11.2
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 5.0 3.2 [2.4–4.0] 84.9 3.3 0.8 2.8 5.0 1.0 2.1
Ceftiofur 0.2 2.9 [2.2–3.7] 0.5 0.9 58.0 36.8 0.7 0.2 0.1 2.8
Ceftriaxone 2.5 0.1 [0.0–0.4] 97.0 0.1 0.0 0.2 1.3 1.2 0.0 0.1
Ciprofloxacin 0.0 0.0 [0.0–0.3] 95.8 1.0 0.3 1.1 0.6 1.2 0.0 0.0
Nalidixic Acid NA 2.9 [2.2–3.7] 0.1 0.5 31.4 63.5 1.2 0.4 2.9
Aminoglycosides Kanamycin 0.1 3.4 [2.7–4.3] 96.4 0.0 0.1 0.2 3.2
Cephamycins Cefoxitin 0.0 3.0 [2.3–3.8] 0.4 35.7 47.0 12.7 1.1 0.0 0.7 2.3
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 1.7 [1.2–2.4] 91.2 6.7 0.3 0.0 1.7
Phenicols Chloramphenicol 0.5 7.8 [6.6–9.0] 2.0 64.2 25.4 0.5 0.1 7.6
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 12.5 [11.1–14.0] 23.7 48.5 14.5 0.7 0.1 12.5
Tetracyclines Tetracycline 0.1 13.7 [12.3–15.3] 86.2 0.1 1.4 4.4 8.0
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for 
resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations 
represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Percent of all isolates with MIC (µg/mL)§
Aminoglycosides






























Table 1.01: Minimum inhibitory concentrations (MICs) and resistance of non-Typhi Salmonella isolates to 
antimicrobial agents, 2005 (N=2052) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.3] 13.3 69.5 15.4 1.7 0.1 0.0
Gentamicin 0.3 2.1 [1.6–2.9] 70.4 25.7 1.3 0.0 0.0 0.3 1.1 1.0
Streptomycin NA 11.0 [9.6–12.4] 89.0 5.9 5.0
Aminopenicillins Ampicillin 0.0 11.3 [10.0–12.8] 76.0 11.9 0.6 0.2 0.1 11.2
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 5.1 3.2 [2.5–4.0] 85.2 2.9 0.8 2.8 5.1 1.0 2.1
Ceftiofur 0.2 2.9 [2.2–3.7] 0.5 0.9 58.2 36.5 0.7 0.2 0.1 2.8
Ceftriaxone 2.5 0.1 [0.0–0.4] 97.0 0.1 0.0 0.2 1.3 1.2 0.0 0.1
Ciprofloxacin 0.0 0.0 [0.0–0.3] 96.2 1.0 0.3 1.1 0.6 0.8 0.0 0.0
Nalidixic Acid NA 2.4 [1.8–3.2] 0.1 0.5 31.5 63.8 1.2 0.4 2.4
Aminoglycosides Kanamycin 0.1 3.4 [2.7–4.3] 96.4 0.0 0.1 0.2 3.2
Cephamycins Cefoxitin 0.0 3.0 [2.3–3.9] 0.4 35.9 47.2 12.3 1.1 0.0 0.7 2.3
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 1.7 [1.2–2.3] 91.2 6.7 0.3 0.0 1.7
Phenicols Chloramphenicol 0.5 7.7 [6.6–9.0] 2.0 64.6 25.1 0.5 0.1 7.6
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 12.5 [11.1–14.0] 23.4 48.7 14.6 0.7 0.1 12.5
Tetracyclines Tetracycline 0.1 13.7 [12.3–15.3] 86.2 0.1 1.4 4.4 8.0
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for 
resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations 
represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
Percent of all isolates with MIC (µg/mL)§
Aminoglycosides































Table 1.02: Percentage and number of non-Typhi Salmonella isolates resistant to antimicrobial agents, 
1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005




Amikacin Not 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 1 0 0 0 0 0 1
Gentamicin 4.8% 2.9% 2.8% 2.1% 2.7% 1.9% 1.3% 1.4% 1.3% 2.1%
(MIC ≥ 16) 63 38 41 32 37 27 27 26 24 44
Streptomycin 20.6% 21.4% 18.6% 16.7% 16.3% 17.0% 13.2% 15.0% 11.8% 11.0%
(MIC ≥ 64) 273 278 272 250 224 241 265 279 212 225
Ampicillin 20.7% 18.3% 16.5% 15.5% 15.9% 17.4% 12.9% 13.6% 12.0% 11.3%
(MIC ≥ 32) 274 238 241 232 219 247 259 254 216 232
Amoxicillin-clavulanic acid 1.1% 1.0% 1.7% 2.3% 3.9% 4.7% 5.3% 4.6% 3.7% 3.2%
(MIC ≥ 32) 15 13 25 34 54 66 106 86 67 65
Ceftiofur 0.2% 0.5% 0.8% 2.0% 3.2% 4.1% 4.3% 4.5% 3.4% 2.9%
(MIC ≥ 8) 2 6 12 30 44 58 87 83 61 60
Ceftriaxone 0.0% 0.1% 0.0% 0.3% 0.0% 0.0% 0.2% 0.4% 0.6% 0.1%
(MIC ≥ 64) 0 1 0 5 0 0 4 8 10 3
Ciprofloxacin 0.0% 0.0% 0.1% 0.1% 0.4% 0.2% 0.0% 0.2% 0.2% 0.0%
(MIC ≥ 4) 0 0 1 1 5 3 1 3 4 1
Nalidixic Acid 0.4% 0.9% 1.4% 0.9% 2.5% 2.6% 1.8% 2.3% 2.6% 2.4%
(MIC ≥ 32) 5 12 20 14 34 37 36 42 47 50
Aminoglycosides Kanamycin 5.0% 5.1% 5.7% 4.3% 5.6% 4.8% 3.8% 3.4% 2.8% 3.4%
(MIC ≥ 64) 66 67 83 65 77 68 76 64 50 70
Cephalothin 2.9% 2.2% 2.3% 3.5% 4.0% 4.0% 5.0% 5.4% Not Not
(MIC ≥ 32) 39 29 33 53 55 57 101 100 Tested Teste
Cefoxitin Not Not Not Not 3.2% 3.4% 4.3% 4.2% 3.5% 3.0%
(MIC ≥ 32) Tested Tested Tested Tested 44 48 86 79 62 62
Trimethoprim-sulfamethoxazole 3.9% 1.8% 2.3% 2.0% 2.1% 2.0% 1.4% 1.9% 1.8% 1.7%
(MIC ≥ 4) 51 24 34 30 29 28 28 36 32 34
Chloramphenicol 10.6% 10.1% 9.9% 9.2% 10.1% 11.6% 8.6% 10.0% 7.6% 7.7%
(MIC ≥ 32) 140 131 145 137 139 164 172 187 136 159
Sulfamethoxazole/Sulfisoxazole* 20.3% 22.8% 19.4% 18.0% 17.1% 17.7% 12.8% 15.0% 13.2% 12.5%
(MIC ≥ 512) 269 297 283 269 235 251 258 280 237 256
Tetracycline 24.2% 21.7% 20.2% 19.3% 18.6% 19.7% 14.9% 16.3% 13.5% 13.7%
(MIC ≥ 16) 320 282 295 289 256 280 299 303 242 282
















Table 1.03: Resistance patterns of non-Typhi Salmonella isolates, 1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Total Isolates 1324 1301 1460 1495 1377 1419 2008 1864 1793 2052
% % % % % % % % % %
n n n n n n n n n n
No resistance detected 66.2% 68.4% 72.9% 74.2% 74.4% 72.3% 79.0% 77.7% 79.6% 80.6%
 876 890 1064 1109 1024 1026 1586 1449 1427 1654
Resistance ≥1CLSI subclass* 33.8% 31.6% 27.1% 25.8% 25.6% 27.7% 21.0% 22.3% 20.4% 19.4%
 448 411 396 386 353 393 422 415 366 398
Resistance ≥2 CLSI subclasses* 27.0% 24.1% 22.6% 20.4% 20.2% 22.1% 15.8% 17.7% 15.0% 14.8%
 358 314 330 305 278 314 318 330 269 304
Resistance ≥3 CLSI subclasses* 18.1% 17.7% 16.7% 15.1% 15.6% 16.8% 12.2% 14.3% 11.7% 12.0%
 240 230 244 225 215 239 244 266 210 247
Resistance ≥4 CLSI subclasses* 13.7% 13.7% 13.1% 12.2% 12.9% 14.2% 9.9% 11.6% 9.4% 9.1%
 181 178 191 183 178 202 199 216 168 186
Resistance ≥5 CLSI subclasses* 10.0% 9.9% 10.1% 8.6% 9.9% 10.5% 8.3% 9.9% 8.1% 7.6%
 132 129 147 129 137 149 167 185 146 156
At least ACSSuT† 8.8% 9.5% 8.9% 8.4% 8.9% 10.0% 7.8% 9.3% 7.1% 6.9%
 116 124 130 125 122 142 156 173 128 141
At least ACSuTm‡ 0.8% 0.4% 0.9% 0.9% 1.0% 0.5% 1.0% 1.2% 0.6% 0.9%
 10 5 13 14 14 7 21 23 10 18
At least ACSSuTAuCf§ 0.0% 0.3% 0.3% 1.5% 2.6% 2.5% 3.3% 3.2% 2.3% 2.0%
 0 4 5 23 36 36 67 60 42 41
At least MDR-AmpC¶ 0.0% 0.3% 0.3% 1.5% 2.6% 2.5% 3.3% 3.2% 2.3% 2.0%
 0 4 5 23 36 36 67 60 42 41
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.2% 0.1% 0.1% 0.3% 0.3% 0.2% 0.2% 0.4% 0.3%
 0 2 1 1 4 4 5 4 7 7
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)     
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Table 1.04: Twenty most common non-Typhi Salmonella serotypes in NARMS and the Public Health 
Laboratory Information System, 2005 
Rank Serotype N (%) Rank Serotype N (%)
1 Typhimurium 437 (21.3%) 1 Typhimurium 6982 (19.5%)
2 Enteritidis 383 (18.7%) 2 Enteritidis 6730 (18.8%)
3 Newport 207 (10.1%) 3 Newport 3295 (9.2%)
4 Heidelberg 125 (6.1%) 4 Heidelberg 1903 (5.3%)
5 Javiana 75 (3.7%) 5 Javiana 1324 (3.7%)
6 Montevideo 48 (2.3%) 6 I 4,[5],12:i:- (monophasic Typhimurium) 822 (2.3%)
7 Braenderup 47 (2.3%) 7 Montevideo 809 (2.3%)
8 Muenchen 44 (2.1%) 8 Muenchen 733 (2.0%)
9 Saintpaul 41 (2.0%) 9 Saintpaul 683 (1.9%)
10 Paratyphi B var. L(+) tartrate+ 38 (1.9%) 10 Braenderup 603 (1.7%)
11 Mississippi 37 (1.8%) 11 Oranienburg 590 (1.6%)
12 I 4,[5],12:i:- (monophasic Typhimurium) 33 (1.6%) 12 Mississippi 565 (1.6%)
13 Oranienburg 33 (1.6%) 13 Infantis 505 (1.4%)
14 Infantis 30 (1.5%) 14 Paratyphi B var. L(+) tartrate+ 460 (1.3%)
15 Thompson 26 (1.3%) 15 Thompson 428 (1.2%)
16 Agona 22 (1.1%) 16 Agona 367 (1.0%)
17 Poona 19 (0.9%) 17 Hartford 239 (0.7%)
18 Stanley 17 (0.8%) 18 Stanley 224 (0.7%)
19 Mbandaka 17 (0.8%) 19 Berta 209 (0.6%)
20 Berta 13 (0.6%) 20 Hadar 205 (0.6%)
Subtotal 1692 (82.5%) Subtotal 27676 (77.2%)
All Other serotypes 336 (16.4%) All Other serotypes 5324 (14.9%)
Unknown serotype 1 (0.0%) Unknown serotype 1113 (3.1%)
Partially serotyped 21 (1.0%) Partially serotyped 1684 (4.7%)
Rough/Nonmotile isolates 2 (0.1%) Rough/Nonmotile isolates 39 (0.1%)
Subtotal 360 (17.5%) Subtotal 8160 (22.8%)








A. Salmonella Typhimurium 
 
In 2005, Typhimurium was the most common non-Typhi Salmonella serotype in NARMS.  ACSSuT in Salmonella 
Typhimurium decreased from 33.7% in 1996 to 22.2% in 2005.  
 
In 2005, Typhimurium was the most common non-Typhi Salmonella serotype in NARMS, accounting for 21.3% 
(437/2052) of non-Typhi Salmonella isolates (Table 1.05). Of the 437 Salmonella Typhimurium isolates tested, 
resistance was highest to sulfisoxazole (31.8%), tetracycline (30.2%), ampicillin (28.8%), streptomycin (27.9%), 
and chloramphenicol (24.3%). The prevalence of resistance among clinically important antimicrobial subclasses 
was 0.9% for quinolones (represented by nalidixic acid) and 2.5% for third-generation cephalosporins 
(represented by ceftiofur). 
 
Resistance to many of the other antimicrobial agents decreased since 1996 (Table 1.06). Resistance to 
tetracycline decreased from 49.3% in 1996 to 30.2% in 2005; ampicillin, from 50.0% to 28.8%; streptomycin, from 
51.6% to 27.9%; chloramphenicol, from 39.9% to 24.3%; and gentamicin, from 4.2% to 1.8%. 
 
Of the 437 Salmonella Typhimurium isolates tested during 2005, 65.2% (285) had no detected resistance, a slight 
increase from the 60.7% of isolates in 2004 (Table 1.07). In 2005, 33.2% (145/437) were resistant to two or more 
CLSI subclasses, compared with 37.2% in 2004. Similarly, in 2005, 23.6% (103/437) were resistant to at least five 
subclasses, compared with 24.3% in 2004. 
 
In 2005, the most common multidrug-resistant phenotype among Salmonella Typhimurium was ACSSuT (22.2% 
of isolates). For Salmonella Typhimurium, ACSSuT commonly is associated with definitive phage type 104.  Since 
1996, the prevalence of ACSSuT among Salmonella Typhimurium decreased from 33.7% to 22.2%. In the logistic 
regression model, this decrease is statistically significant (OR=0.6, 95% CI [0.4, 0.8]). 
 
One (0.2%) serotype Typhimurium isolate was resistant to both quinolones and third-generation cephalosporins in 
2005. Since 1996, seven Salmonella Typhimurium isolates have shown this multidrug resistance pattern. 
 
28 
Table 1.05: Minimum inhibitory concentrations (MICs) and resistance of Salmonella Typhimurium isolates 
to antimicrobial agents, 2005 (N=437) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–0.8] 3.9 75.3 17.6 3.2
Gentamicin 0.2 1.8 [0.8–3.6] 66.1 29.7 2.1 0.2 1.1 0.7
Streptomycin NA 27.9 [23.8–32.4] 72.1 18.3 9.6
Aminopenicillins Ampicillin 0.0 28.8 [24.6–33.3] 63.4 7.6 0.2 28.8
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 19.0 3.2 [1.8–5.3] 68.9 2.1 0.5 6.4 19.0 1.1 2.1
Ceftiofur 0.2 2.5 [1.3–4.5] 0.2 0.7 60.2 35.2 0.9 0.2 2.5
Ceftriaxone 2.1 0.0 [0.0–0.8] 97.5 0.5 1.1 0.9
Ciprofloxacin 0.0 0.0 [0.0–0.8] 97.3 1.4 0.7 0.2 0.2 0.2
Nalidixic Acid NA 0.9 [0.2–2.3] 0.2 0.5 37.3 59.7 0.9 0.5 0.9
Aminoglycosides Kanamycin 0.0 5.7 [3.7–8.3] 94.1 0.2 0.5 5.3
Cephamycins Cefoxitin 0.0 2.5 [1.3–4.5] 34.3 54.5 7.3 1.4 0.5 2.1
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 2.7 [1.4–4.7] 78.5 18.1 0.7 2.7
Phenicols Chloramphenicol 0.2 24.3 [20.3–28.6] 1.4 55.6 18.5 0.2 0.5 23.8
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 31.8 [27.5–36.4] 20.1 43.5 4.3 0.2 31.8
Tetracyclines Tetracycline 0.2 30.2 [25.9–34.7] 69.6 0.2 5.5 14.6 10.1
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
Quinolones
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides
































Table 1.06: Percentage and number of Salmonella Typhimurium isolates resistant to antimicrobial agents, 
1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0
Gentamicin 4.2% 4.6% 3.7% 2.2% 2.6% 1.5% 2.3% 2.0% 2.1% 1.8%
(MIC ≥ 16) 13 15 14 8 8 5 9 8 8 8
Streptomycin 51.6% 55.2% 47.5% 43.1% 39.5% 40.0% 31.8% 35.2% 31.7% 27.9%
(MIC ≥ 64) 158 181 180 156 120 130 125 143 121 122
Ampicillin 50.0% 50.3% 45.4% 41.2% 42.1% 42.5% 33.6% 36.0% 31.9% 28.8%
(MIC ≥ 32) 153 165 172 149 128 138 132 146 122 126
Amoxicillin-clavulanic acid 2.6% 3.4% 4.5% 2.8% 6.3% 6.2% 7.6% 5.4% 4.7% 3.2%
(MIC ≥ 32) 8 11 17 10 19 20 30 22 18 14
Ceftiofur 0.0% 1.5% 1.8% 1.9% 3.6% 3.1% 4.3% 4.9% 4.5% 2.5%
(MIC ≥ 8) 0 5 7 7 11 10 17 20 17 11
Ceftriaxone 0.0% 0.3% 0.0% 0.3% 0.0% 0.0% 0.3% 0.2% 0.8% 0.0%
(MIC ≥ 64) 0 1 0 1 0 0 1 1 3 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 1 0 0 0 0
Nalidixic Acid 0.3% 0.9% 0.5% 0.0% 1.3% 0.6% 1.3% 1.2% 0.5% 0.9%
(MIC ≥ 32) 1 3 2 0 4 2 5 5 2 4
Aminoglycosides Kanamycin 14.4% 15.5% 15.8% 13.0% 13.2% 8.3% 7.6% 7.1% 5.8% 5.7%
(MIC ≥ 64) 44 51 60 47 40 27 30 29 22 25
Cephalothin 2.0% 4.3% 4.0% 4.4% 4.3% 3.1% 5.6% 6.2% Not Not
(MIC ≥ 32) 6 14 15 16 13 10 22 25 Tested Tested
Cefoxitin Not Not Not Not 3.6% 3.1% 4.3% 4.4% 4.7% 2.5%
(MIC ≥ 32) Tested Tested Tested Tested 11 10 17 18 18 11
Trimethoprim-sulfamethoxazole 4.6% 3.0% 4.5% 2.8% 3.6% 2.5% 2.3% 3.4% 2.6% 2.7%
(MIC ≥ 4) 14 10 17 10 11 8 9 14 10 12
Chloramphenicol 39.9% 36.0% 33.8% 28.7% 30.9% 31.7% 23.2% 27.8% 24.1% 24.3%
(MIC ≥ 32) 122 118 128 104 94 103 91 113 92 106
Sulfamethoxazole/Sulfisoxazole* 53.3% 56.7% 49.9% 45.6% 45.4% 43.1% 32.1% 38.4% 35.9% 31.8%
(MIC ≥ 512) 163 186 189 165 138 140 126 156 137 139
Tetracycline 49.3% 52.4% 46.2% 41.7% 43.4% 43.4% 31.8% 37.9% 30.1% 30.2%
(MIC ≥ 16) 151 172 175 151 132 141 125 154 115 132














Table 1.07: Resistance patterns of Salmonella Typhimurium isolates, 1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Total Isolates 306 328 379 362 304 325 393 406 382 437
% % % % % % % % % %
n n n n n n n n n n
No resistance detected 37.9% 39.0% 46.7% 50.6% 49.3% 49.2% 60.3% 54.9% 60.7% 65.2%
 116 128 177 183 150 160 237 223 232 285
Resistance ≥1CLSI subclass* 62.1% 61.0% 53.3% 49.4% 50.7% 50.8% 39.7% 45.1% 39.3% 34.8%
 190 200 202 179 154 165 156 183 150 152
Resistance ≥2 CLSI subclasses* 56.2% 56.7% 51.2% 46.1% 47.0% 48.0% 36.1% 41.4% 37.2% 33.2%
 172 186 194 167 143 156 142 168 142 145
Resistance ≥3 CLSI subclasses* 51.0% 52.4% 47.5% 43.1% 43.4% 41.8% 32.3% 36.9% 31.4% 30.0%
 156 172 180 156 132 136 127 150 120 131
Resistance ≥4 CLSI subclasses* 45.4% 47.9% 43.0% 38.4% 39.8% 38.2% 28.5% 32.0% 28.0% 27.2%
 139 157 163 139 121 124 112 130 107 119
Resistance ≥5 CLSI subclasses* 35.6% 36.0% 34.3% 27.9% 30.6% 29.8% 23.4% 27.8% 24.3% 23.6%
 109 118 130 101 93 97 92 113 93 103
At least ACSSuT† 33.7% 35.1% 32.2% 27.6% 28.0% 29.5% 21.4% 26.1% 23.3% 22.2%
 103 115 122 100 85 96 84 106 89 97
At least ACSuTm‡ 2.0% 0.6% 2.6% 2.2% 1.6% 0.9% 2.0% 3.2% 1.6% 2.1%
 6 2 10 8 5 3 8 13 6 9
At least ACSSuTAuCf§ 0.0% 1.2% 1.1% 0.6% 2.0% 1.2% 1.8% 2.2% 2.6% 1.8%
 0 4 4 2 6 4 7 9 10 8
At least MDR-AmpC¶ 0.0% 1.2% 1.1% 0.6% 2.0% 1.2% 1.8% 2.2% 2.6% 1.8%
 0 4 4 2 6 4 7 9 10 8
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.3% 0.0% 0.0% 0.3% 0.3% 0.5% 0.0% 0.3% 0.2%
 0 1 0 0 1 1 2 0 1 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 





B. Salmonella Enteritidis 
 
In 2005, Enteritidis was the second most common non-Typhi Salmonella serotype in NARMS.  Most Salmonella 
Enteritidis isolates had no detected resistance.  However, nalidixic acid resistance increased from 0.9% in 1996 to 
4.7% in 2005. 
 
In 2005, Enteritidis was the second most common non-Typhi Salmonella serotype identified in NARMS, 
accounting for 18.6% (383/2052) of non-Typhi Salmonella isolates (Table 1.04). Among Salmonella Enteritidis 
isolates tested in 2005, resistance was rare.  The most dramatic increase occurred with nalidixic acid.  There is a 
statistically significant increase in nalidixic acid resistance from 0.9% in 1996 to 4.7% in 2005 (95% CI [1.6, 30.5]) 
(Table 1.09).  Salmonella Enteritidis was the second most prevalent (30.5%) non-Typhi Salmonella serotype that 
had resistance to nalidixic acid (Table 1.20). 
 
Most (91.9%) of the Salmonella Enteritidis isolates tested in 2005 had no detected resistance (Table 1.10).  
Multidrug resistance was rare.  
 
 
Table 1.08: Minimum inhibitory concentrations (MICs) and resistance of Salmonella Enteritidis isolates to 
antimicrobial agents, 2005 (N=383) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.0] 30.5 61.1 8.4
Gentamicin 0.0 0.8 [0.2–2.3] 86.2 13.1 0.5 0.3
Streptomycin NA 1.0 [0.3–2.7] 99.0 0.3 0.8
Aminopenicillins Ampicillin 0.0 2.9 [1.4–5.1] 72.1 24.3 0.5 0.3 0.3 2.6
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 1.0 0.8 [0.2–2.3] 93.5 3.1 0.5 1.0 1.0 0.5 0.3
Ceftiofur 0.3 0.5 [0.1–1.9] 0.3 0.8 36.3 61.6 0.3 0.3 0.3 0.3
Ceftriaxone 0.3 0.0 [0.0–1.0] 99.5 0.3 0.3
Ciprofloxacin 0.0 0.0 [0.0–1.0] 94.5 0.5 1.0 3.1 0.8
Nalidixic Acid NA 4.7 [2.8–7.3] 14.1 78.6 2.6 4.7
Aminoglycosides Kanamycin 0.3 0.3 [0.0–1.4] 99.5 0.3 0.3
Cephamycins Cefoxitin 0.0 1.0 [0.3–2.7] 0.5 34.2 59.0 4.7 0.5 0.5 0.5
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.5 [0.1–1.9] 97.7 1.6 0.3 0.5
Phenicols Chloramphenicol 0.3 0.5 [0.1–1.9] 1.0 77.3 20.9 0.3 0.5
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 1.6 [0.6–3.4] 22.2 63.4 12.0 0.5 0.3 1.6
Tetracyclines Tetracycline 0.0 2.3 [1.1–4.4] 97.7 2.3
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides






























Table 1.09: Percentage and number of Salmonella Enteritidis isolates resistant to antimicrobial agents, 
1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0
Gentamicin 4.8% 0.3% 0.4% 0.0% 0.3% 0.0% 0.3% 0.4% 0.4% 0.8%
(MIC ≥ 16) 17 1 1 0 1 0 1 1 1 3
Streptomycin 2.0% 4.3% 1.6% 2.2% 0.0% 1.4% 1.8% 1.2% 2.2% 1.0%
(MIC ≥ 64) 7 13 4 6 0 4 6 3 6 4
Ampicillin 20.5% 11.3% 6.1% 10.8% 7.5% 8.7% 7.1% 2.3% 4.1% 2.9%
(MIC ≥ 32) 72 34 15 29 24 24 24 6 11 11
Amoxicillin-clavulanic acid 0.6% 0.0% 0.0% 0.4% 0.0% 1.4% 0.6% 0.0% 0.0% 0.8%
(MIC ≥ 32) 2 0 0 1 0 4 2 0 0 3
Ceftiofur 0.0% 0.3% 0.0% 0.4% 0.0% 2.2% 0.0% 0.0% 0.0% 0.5%
(MIC ≥ 8) 0 1 0 1 0 6 0 0 0 2
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic Acid 0.9% 1.7% 2.0% 2.2% 2.2% 4.3% 3.9% 4.7% 6.6% 4.7%
(MIC ≥ 32) 3 5 5 6 7 12 13 12 18 18
Aminoglycosides Kanamycin 0.0% 0.7% 0.4% 0.4% 0.3% 0.7% 0.3% 0.0% 0.7% 0.3%
(MIC ≥ 64) 0 2 1 1 1 2 1 0 2 1
Cephalothin 4.0% 1.3% 0.0% 1.9% 0.9% 1.1% 0.6% 1.2% Not Not
(MIC ≥ 32) 14 4 0 5 3 3 2 3 Tested Teste
Cefoxitin Not Not Not Not 0.0% 0.4% 0.0% 0.0% 0.0% 1.0%
(MIC ≥ 32) Tested Tested Tested Tested 0 1 0 0 0 4
Trimethoprim-sulfamethoxazole 6.6% 1.3% 0.8% 0.7% 0.0% 0.7% 0.6% 0.8% 0.0% 0.5%
(MIC ≥ 4) 23 4 2 2 0 2 2 2 0 2
Chloramphenicol 0.0% 0.7% 0.0% 0.4% 0.0% 0.0% 0.6% 0.4% 0.4% 0.5%
(MIC ≥ 32) 0 2 0 1 0 0 2 1 1 2
Sulfamethoxazole/Sulfisoxazole* 8.5% 9.0% 2.0% 3.0% 0.9% 2.2% 1.8% 1.2% 1.8% 1.6%
(MIC ≥ 512) 30 27 5 8 3 6 6 3 5 6
Tetracycline 16.8% 9.6% 6.6% 8.2% 1.9% 1.8% 4.5% 1.6% 3.3% 2.3%
(MIC ≥ 16) 59 29 16 22 6 5 15 4 9 9
















Table 1.10: Resistance patterns of Salmonella Enteritidis isolates, 1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Total Isolates 351 301 244 269 319 277 337 257 271 383
% % % % % % % % % %
n n n n n n n n n n
No resistance detected 73.5% 77.4% 87.7% 83.6% 89.0% 86.6% 87.2% 91.8% 87.1% 91.9%
 258 233 214 225 284 240 294 236 236 352
Resistance ≥1CLSI subclass* 26.5% 22.6% 12.3% 16.4% 11.0% 13.4% 12.8% 8.2% 12.9% 8.1%
 93 68 30 44 35 37 43 21 35 31
Resistance ≥2 CLSI subclasses* 19.1% 9.6% 6.6% 8.6% 1.9% 4.7% 4.2% 2.3% 3.0% 3.7%
 67 29 16 23 6 13 14 6 8 14
Resistance ≥3 CLSI subclasses* 8.0% 3.0% 0.8% 1.1% 0.3% 2.9% 2.4% 0.8% 1.1% 2.1%
 28 9 2 3 1 8 8 2 3 8
Resistance ≥4 CLSI subclasses* 4.6% 1.3% 0.0% 0.7% 0.0% 1.8% 1.5% 0.4% 0.7% 0.8%
 16 4 0 2 0 5 5 1 2 3
Resistance ≥5 CLSI subclasses* 1.7% 0.7% 0.0% 0.4% 0.0% 0.0% 0.3% 0.4% 0.7% 0.5%
 6 2 0 1 0 0 1 1 2 2
At least ACSSuT† 0.0% 0.3% 0.0% 0.4% 0.0% 0.0% 0.3% 0.4% 0.4% 0.5%
 0 1 0 1 0 0 1 1 1 2
At least ACSuTm‡ 0.0% 0.3% 0.0% 0.4% 0.0% 0.0% 0.0% 0.4% 0.0% 0.0%
 0 1 0 1 0 0 0 1 0 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3%
 0 0 0 1 0 0 0 0 0 1
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3%
 0 0 0 1 0 0 0 0 0 1
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.3% 0.0% 0.0% 0.3% 0.0% 0.0% 0.4% 0.0% 0.3%
 0 1 0 0 1 0 0 1 0 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 





C. Salmonella Newport 
 
In 2005, Newport was the third most common non-Typhi Salmonella serotype in NARMS.  MDR-AmpC in 
Salmonella Newport increased from 1996 to 2005, which was similar to the trend in ceftiofur resistance.  MDR-
AmpC was first noted in 1998, increased to 18.2% in 1999, peaked at 25.0% in 2001, and declined to 12.6% in 
2005.  
 
In 2005, Newport was the third most commonly isolated non-Typhi Salmonella serotype in NARMS, accounting 
for 10.0% (207/2052) of non-Typhi Salmonella isolates (Table 1.04). The highest proportions of the Salmonella 
Newport isolates tested were resistant to sulfisoxazole (15.5%), tetracycline (14.5%), ampicillin (14.0%), 
streptomycin (14.0%), chloramphenicol (13.5%) amoxicillin-clavulanic acid (12.6%), ceftiofur (12.6%), and 
cefoxitin (12.6%). The prevalence of resistance among clinically important antimicrobial subclasses was 0.0% for 
quinolones (represented by nalidixic acid) and 12.6% for third-generation cephalosporins (represented by 
ceftiofur).
 
Ceftiofur resistance was first noted in one isolate (1.3%) in 1998; it increased to 18.2% in 1999, peaked at 27.4% 
in 2001, and declined to 12.6% in 2005 (Table 1.12). Salmonella Newport was the most prevalent (43.3%) non-
Typhi Salmonella serotype that had resistance to ceftiofur (Table 1.20).  
 
In contrast to other common serotypes, the percentage of Salmonella Newport isolates with no detected 
resistance declined from 86.3% in 1996 and 73.5% in 2003 (Table 1.13). However, the percentage of Salmonella 
Newport isolates with no detected resistance was higher in 2005 (84.1%) than in 2004 (82.2%). In addition, 
resistance to at least five subclasses of antimicrobial agents increased from 5.9% in 1996 to 12.6% in 2005; it 
peaked in 2001, similar to the trend in ceftiofur resistance. 
 
In 2005, MDR-AmpC was among the most common multidrug-resistant phenotype in serotype Newport (12.6% of 
isolates). MDR-AmpC increased since 1996, which was similar to the trend in ceftiofur resistance (Table 1.13); it 
was first noted in 1998, increased to 18.2% in 1999, peaked at 25.0% in 2001, and declined to 12.6% in 2005. In 
the logistic regression model, the increase from 1996 to 2005 was statistically significant (95% CI [1.8, infinity]). 
 
 
Table 1.11: Minimum inhibitory concentrations (MICs) and resistance of Salmonella Newport isolates to 
antimicrobial agents, 2005 (N=207) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.8] 8.2 75.4 13.0 3.4
Gentamicin 1.0 1.0 [0.1–3.4] 75.8 21.7 0.5 1.0 1.0
Streptomycin NA 14.0 [9.6–19.5] 86.0 1.0 13.0
Aminopenicillins Ampicillin 0.0 14.0 [9.6–19.5] 82.1 3.4 0.5 14.0
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.0 12.6 [8.4–17.9] 85.0 0.5 0.5 1.4 4.3 8.2
Ceftiofur 0.0 12.6 [8.4–17.9] 0.5 58.9 27.5 0.5 12.6
Ceftriaxone 11.1 1.4 [0.3–4.2] 87.4 4.3 6.8 0.5 1.0
Ciprofloxacin 0.0 0.0 [0.0–1.8] 100.0
Nalidixic Acid NA 0.0 [0.0–1.8] 1.4 33.8 64.7
Aminoglycosides Kanamycin 0.0 1.9 [0.5–4.9] 98.1 1.9
Cephamycins Cefoxitin 0.0 12.6 [8.4–17.9] 0.5 41.1 42.5 2.4 1.0 1.0 11.6
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 1.9 [0.5–4.9] 94.7 3.4 1.9
Phenicols Chloramphenicol 0.0 13.5 [9.2–19.0] 5.3 75.4 5.8 13.5
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 15.5 [10.8–21.1] 4.8 44.0 33.8 1.9 15.5
Tetracyclines Tetracycline 0.0 14.5 [10.0–20.0] 85.5 3.4 11.1
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides


































Table 1.12: Percentage and number of Salmonella Newport isolates resistant to antimicrobial agents, 
1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0
Gentamicin 5.9% 4.3% 0.0% 0.0% 2.5% 3.2% 3.3% 3.1% 0.5% 1.0%
(MIC ≥ 16) 3 2 0 0 3 4 8 7 1 2
Streptomycin 7.8% 4.3% 2.6% 19.2% 24.0% 31.5% 25.3% 24.2% 15.7% 14.0%
(MIC ≥ 64) 4 2 2 19 29 39 61 54 30 29
Ampicillin 5.9% 6.5% 2.6% 18.2% 23.1% 29.8% 24.9% 22.9% 15.7% 14.0%
(MIC ≥ 32) 3 3 2 18 28 37 60 51 30 29
Amoxicillin-clavulanic acid 2.0% 0.0% 2.6% 18.2% 22.3% 26.6% 22.8% 21.5% 15.2% 12.6%
(MIC ≥ 32) 1 0 2 18 27 33 55 48 29 26
Ceftiofur 0.0% 0.0% 1.3% 18.2% 22.3% 27.4% 22.8% 22.0% 15.2% 12.6%
(MIC ≥ 8) 0 0 1 18 27 34 55 49 29 26
Ceftriaxone 0.0% 0.0% 0.0% 3.0% 0.0% 0.0% 0.8% 1.8% 2.6% 1.4%
(MIC ≥ 64) 0 0 0 3 0 0 2 4 5 3
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic Acid 0.0% 0.0% 0.0% 0.0% 0.8% 0.0% 0.8% 0.4% 0.5% 0.0%
(MIC ≥ 32) 0 0 0 0 1 0 2 1 1 0
Aminoglycosides Kanamycin 2.0% 0.0% 1.3% 1.0% 5.0% 7.3% 10.0% 4.5% 2.6% 1.9%
(MIC ≥ 64) 1 0 1 1 6 9 24 10 5 4
Cephalothin 3.9% 4.3% 2.6% 18.2% 22.3% 26.6% 22.8% 22.4% Not Not
(MIC ≥ 32) 2 2 2 18 27 33 55 50 Tested Tested
Cefoxitin Not Not Not Not 22.3% 25.8% 22.4% 21.5% 15.2% 12.6%
(MIC ≥ 32) Tested Tested Tested Tested 27 32 54 48 29 26
Trimethoprim-sulfamethoxazole 3.9% 4.3% 1.3% 2.0% 4.1% 1.6% 4.1% 0.9% 2.1% 1.9%
(MIC ≥ 4) 2 2 1 2 5 2 10 2 4 4
Chloramphenicol 5.9% 4.3% 2.6% 18.2% 23.1% 28.2% 25.3% 22.4% 15.2% 13.5%
(MIC ≥ 32) 3 2 2 18 28 35 61 50 29 28
Sulfamethoxazole/Sulfisoxazole* 11.8% 4.3% 3.9% 22.2% 23.1% 32.3% 25.7% 24.7% 16.8% 15.5%
(MIC ≥ 512) 6 2 3 22 28 40 62 55 32 32
Tetracycline 7.8% 4.3% 2.6% 19.2% 23.1% 30.6% 25.7% 24.2% 16.8% 14.5%
(MIC ≥ 16) 4 2 2 19 28 38 62 54 32 30

















Table 1.13: Resistance patterns of Salmonella Newport isolates, 1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Total Isolates 51 46 77 99 121 124 241 223 191 207
% % % % % % % % % %
n n n n n n n n n n
No resistance detected 86.3% 93.5% 94.8% 75.8% 75.2% 65.3% 72.2% 73.5% 82.2% 84.1%
 44 43 73 75 91 81 174 164 157 174
Resistance ≥1CLSI subclass* 13.7% 6.5% 5.2% 24.2% 24.8% 34.7% 27.8% 26.5% 17.8% 15.9%
 7 3 4 24 30 43 67 59 34 33
Resistance ≥2 CLSI subclasses* 7.8% 4.3% 2.6% 18.2% 23.1% 32.3% 25.7% 25.1% 17.3% 15.0%
 4 2 2 18 28 40 62 56 33 31
Resistance ≥3 CLSI subclasses* 5.9% 4.3% 2.6% 18.2% 23.1% 31.5% 25.3% 23.3% 16.8% 14.5%
 3 2 2 18 28 39 61 52 32 30
Resistance ≥4 CLSI subclasses* 5.9% 4.3% 2.6% 18.2% 23.1% 31.5% 25.3% 22.9% 15.7% 14.0%
 3 2 2 18 28 39 61 51 30 29
Resistance ≥5 CLSI subclasses* 5.9% 4.3% 2.6% 18.2% 23.1% 27.4% 23.7% 22.4% 14.7% 12.6%
 3 2 2 18 28 34 57 50 28 26
At least ACSSuT† 5.9% 4.3% 1.3% 18.2% 23.1% 25.8% 23.7% 22.0% 14.7% 12.6%
 3 2 1 18 28 32 57 49 28 26
At least ACSuTm‡ 3.9% 4.3% 1.3% 2.0% 4.1% 0.8% 3.7% 0.9% 1.0% 1.9%
 2 2 1 2 5 1 9 2 2 4
At least ACSSuTAuCf§ 0.0% 0.0% 1.3% 18.2% 22.3% 25.0% 22.8% 21.1% 14.7% 12.6%
 0 0 1 18 27 31 55 47 28 26
At least MDR-AmpC¶ 0.0% 0.0% 1.3% 18.2% 22.3% 25.0% 22.8% 21.1% 14.7% 12.6%
 0 0 1 18 27 31 55 47 28 26
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 1.3% 0.0% 0.0% 0.0% 0.4% 0.0% 0.5% 0.0%
 0 0 1 0 0 0 1 0 1 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)    
  
D. Salmonella Heidelberg 
 
In 2005, Heidelberg was the fourth most commonly isolated non-Typhi Salmonella serotype in NARMS, 
accounting for 6.1% (125/2052) of non-Typhi Salmonella isolates (Table 1.04). The highest proportions of the 
Salmonella Heidelberg isolates tested were resistant to ampicillin (20.0%), tetracycline (18.4%), streptomycin 
(13.6%), kanamycin (12.8%) amoxicillin-clavulanic acid, ceftiofur, and cefoxitin (8.8%) and sulfisoxazole (8.0%). 
The prevalence of resistance among clinically important antimicrobial subclasses was 1.7% for quinolones 
(represented by nalidixic acid) and 18.3% for third-generation cephalosporins (represented by ceftiofur) (Table 
1.20).
 
Ceftiofur resistance was first noted in one isolate (1.3%) in 1996; it increased to 9.7% in 2004 and decreased to 
8.8% in 2005 (Table 1.15). Salmonella Heidelberg was the second most common serotype (18.3%), tied with 
Typhimurium, among ceftiofur-resistant non-Typhi Salmonella (Table 1.20).  
 
In contrast to other common serotypes, the percentage of Salmonella Heidelberg isolates with no detected 
resistance increased from 54.1% in 1996 and 62.4% in 2005 (Table 1.16). In addition, resistance to at least five 
subclasses of antimicrobial agents decreased from 3.2% in 2004 to 2.4% in 2005. 
 
In 2005, one Salmonella Heidelberg isolate was found to have the combination of quinolone and third-generation 
cephalosporin resistance (Table 1.16).  
 
36 
Table 1.14: Minimum inhibitory concentrations (MICs) and resistance of Salmonella Heidelberg isolates to 
antimicrobial agents, 2005 (N=125) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–2.9] 26.4 63.2 8.8 0.8 0.8
Gentamicin 0.8 6.4 [2.8–12.2] 73.6 16.0 2.4 0.8 0.8 3.2 3.2
Streptomycin NA 13.6 [8.1–20.9] 86.4 7.2 6.4
Aminopenicillins Ampicillin 0.0 20.0 [13.4–28.1] 62.4 16.8 0.8 20.0
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 4.8 8.8 [4.5–15.2] 77.6 1.6 0.8 6.4 4.8 2.4 6.4
Ceftiofur 0.0 8.8 [4.5–15.2] 1.6 73.6 15.2 0.8 8.8
Ceftriaxone 7.2 0.0 [0.0–2.9] 91.2 1.6 6.4 0.8
Ciprofloxacin 0.0 0.0 [0.0–2.9] 99.2 0.8
Nalidixic Acid NA 0.8 [0.0–4.4] 20.8 77.6 0.8 0.8
Aminoglycosides Kanamycin 0.0 12.8 [7.5–20.0] 87.2 12.8
Cephamycins Cefoxitin 0.0 8.8 [4.5–15.2] 59.2 26.4 4.0 1.6 4.8 4.0
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.8 [0.0–4.4] 96.0 3.2 0.8
Phenicols Chloramphenicol 0.8 0.8 [0.0–4.4] 0.8 61.6 36.0 0.8 0.8
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 0.0 [3.9–14.2] 50.4 37.6 4.0 8.0
Tetracyclines Tetracycline 0.0 18.4 [12.0–26.3] 81.6 1.6 16.8
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides































Table 1.15: Percentage and number of Salmonella Heidelberg isolates resistant to antimicrobial agents, 
1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0
Gentamicin 23.0% 17.3% 16.8% 14.8% 8.9% 7.8% 3.8% 5.2% 4.3% 6.4%
(MIC ≥ 16) 17 13 17 13 7 8 4 5 4 8
Streptomycin 40.5% 24.0% 30.7% 23.9% 22.8% 25.5% 17.1% 12.5% 15.1% 13.6%
(MIC ≥ 64) 30 18 31 21 18 26 18 12 14 17
Ampicillin 14.9% 13.3% 16.8% 6.8% 10.1% 9.8% 12.4% 10.4% 25.8% 20.0%
(MIC ≥ 32) 11 10 17 6 8 10 13 10 24 25
Amoxicillin-clavulanic acid 2.7% 1.3% 1.0% 1.1% 3.8% 2.9% 9.5% 5.2% 10.8% 8.8%
(MIC ≥ 32) 2 1 1 1 3 3 10 5 10 11
Ceftiofur 1.4% 0.0% 0.0% 0.0% 3.8% 2.9% 7.6% 5.2% 9.7% 8.8%
(MIC ≥ 8) 1 0 0 0 3 3 8 5 9 11
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic Acid 0.0% 0.0% 1.0% 1.1% 1.3% 0.0% 0.0% 1.0% 0.0% 0.8%
(MIC ≥ 32) 0 0 1 1 1 0 0 1 0 1
Aminoglycosides Kanamycin 14.9% 8.0% 12.9% 9.1% 15.2% 19.6% 10.5% 8.3% 8.6% 12.8%
(MIC ≥ 64) 11 6 13 8 12 20 11 8 8 16
Cephalothin 6.8% 2.7% 5.9% 3.4% 5.1% 3.9% 10.5% 7.3% Not Not
(MIC ≥ 32) 5 2 6 3 4 4 11 7 Tested Teste
Cefoxitin Not Not Not Not 2.5% 2.9% 8.6% 5.2% 8.6% 8.8%
(MIC ≥ 32) Tested Tested Tested Tested 2 3 9 5 8 11
Trimethoprim-sulfamethoxazole 0.0% 0.0% 2.0% 1.1% 1.3% 2.0% 1.0% 2.1% 0.0% 0.8%
(MIC ≥ 4) 0 0 2 1 1 2 1 2 0 1
Chloramphenicol 1.4% 0.0% 1.0% 1.1% 1.3% 1.0% 1.0% 0.0% 1.1% 0.8%
(MIC ≥ 32) 1 0 1 1 1 1 1 0 1 1
Sulfamethoxazole/Sulfisoxazole* 17.6% 21.3% 21.8% 18.2% 11.4% 8.8% 6.7% 7.3% 7.5% 8.0%
(MIC ≥ 512) 13 16 22 16 9 9 7 7 7 10
Tetracycline 20.3% 12.0% 19.8% 18.2% 21.5% 24.5% 19.0% 16.7% 19.4% 18.4%
(MIC ≥ 16) 15 9 20 16 17 25 20 16 18 23


















Table 1.16: Resistance patterns of Salmonella Heidelberg isolates, 1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Total Isolates 74 75 101 88 79 102 105 96 93 125
% % % % % % % % % %
n n n n n n n n n n
No resistance detected 54.1% 66.7% 56.4% 68.2% 63.3% 64.7% 67.6% 68.8% 55.9% 62.4%
 40 50 57 60 50 66 71 66 52 78
Resistance ≥1CLSI subclass* 45.9% 33.3% 43.6% 31.8% 36.7% 35.3% 32.4% 31.3% 44.1% 37.6%
 34 25 44 28 29 36 34 30 41 47
Resistance ≥2 CLSI subclasses* 33.8% 26.7% 33.7% 26.1% 26.6% 29.4% 25.7% 17.7% 23.7% 24.8%
 25 20 34 23 21 30 27 17 22 31
Resistance ≥3 CLSI subclasses* 12.2% 12.0% 13.9% 10.2% 7.6% 7.8% 11.4% 10.4% 14.0% 15.2%
 9 9 14 9 6 8 12 10 13 19
Resistance ≥4 CLSI subclasses* 4.1% 1.3% 4.0% 4.5% 3.8% 2.0% 1.9% 2.1% 4.3% 4.8%
 3 1 4 4 3 2 2 2 4 6
Resistance ≥5 CLSI subclasses* 2.7% 1.3% 1.0% 0.0% 3.8% 2.0% 1.9% 0.0% 3.2% 2.4%
 2 1 1 0 3 2 2 0 3 3
At least ACSSuT† 1.4% 0.0% 0.0% 0.0% 1.3% 1.0% 1.0% 0.0% 1.1% 0.0%
 1 0 0 0 1 1 1 0 1 0
At least ACSuTm‡ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 1 0 0 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 1.3% 1.0% 1.0% 0.0% 0.0% 0.0%
 0 0 0 0 1 1 1 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 1.3% 1.0% 1.0% 0.0% 0.0% 0.0%
 0 0 0 0 1 1 1 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.8%
 0 0 0 0 0 0 0 0 0 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 









Salmonella Heidelberg is one of the leading non-Typhi Salmonella serotypes.  In 2005, it ranked 5th among 
human non-Typhi Salmonella isolates tested by the National Antimicrobial Resistance Monitoring (NARMS) and 
among culture-confirmed infections reported to National Salmonella Surveillance System at CDC 
(http://www.cdc.gov/ncidod/dbmd/phlisdata/default.htm).  It is one of the most common serotypes among non-
Typhi Salmonella isolates reported from retail poultry (http://www.fda.gov/cvm/2005NARMSAnnualRpt.htm) and 
food animals (http://www.ars.usda.gov/Main/docs.htm?docid=16598).  Ceftriaxone, a third-generation 
cephalosporin used to treat invasive Salmonella infections in children, is closely related to ceftiofur, a third-
generation cephalosporin used in food animals in the United States.  Ceftiofur resistance has been associated 
with decreased susceptibility to ceftriaxone (Medalla et al., ICEID 2006).  Molecular biological analyses of 
extended-spectrum cephalosporin-resistant strains of Salmonella have revealed that resistance is primarily 
associated with plasmids (designated types A, B, C, and D) that carry the blaCMY-2 gene.  These data suggest that 
the blaCMY-2 gene has been disseminated among Salmonella strains primarily through plasmid transfer (Carattoli 
et al., Antimicrob Agents Chemother 2002, 46:1269-72; Giles et al., Antimicrob Agents Chemother 2004, 48:2845-
52). 
 
Although ceftriaxone resistance is rare among non-Typhi Salmonella submitted to NARMS, an increase in 
ceftiofur resistance since 1996 has been seen.  This increase was mainly driven by an increase in the so-called 
“MDR-AmpC” phentoype in serotype Newport (Gupta et al., J Infect Dis 2003, 188:1707-16).  MDR-AmpC is 
defined as resistance to at least ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin-
clavulanic acid, and ceftiofur, and decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL).  From 1996 to 2005, 
MDR-AmpC was noted in 12 serotypes in addition to Newport.    Here we describe the trend in ceftiofur resistance 
in Salmonella Heidelberg in NARMS from 1996-2005.  Isolate submission and testing are described in the 
methods section of this report. 
 
From 1996-2005, 938 (5.8%) of 16,093 non-Typhi Salmonella isolates were serotype Heidelberg. Of 938 
Heidelberg isolates, 40 (4.3%) were ceftiofur-resistant. Ceftiofur resistance increased from 1.4% in 1996 to 8.8% 
in 2005 [Figure 1]. Decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL) showed the same trend [Figure 1]. In 
contrast to an increase in MDR-AmpC observed with the emergence of extended-spectrum cephalosporin 
resistance among serotype Newport, only 3 of the ceftiofur-resistant Heidelberg isolates were MDR-AmpC.  
NARMS is characterizing the genetic elements involved in the dissemination of the blaCMY genes that confer 
extended-spectrum cephalosporin resistance in Salmonella Heidelberg. 
 
 
Figure 1: Percentage of Salmonella Heidelberg with ceftiofur resistance  






































E. Salmonella I 4,[5],12:i:- 
 
In 2005, I 4,[5],12:i:- was the twelfth most common non-Typhi Salmonella serotype in NARMS.   Most Salmonella 
I 4,[5],12:i:-  isolates had no detected resistance. Multidrug resistance was not common in this serotype. 
 
In 2005, I 4,[5],12:i:- was the twelfth most commonly isolated non-Typhi Salmonella serotype in NARMS, 
accounting for 1.6% (33/2052) of non-Typhi Salmonella isolates (Table 1.04). The highest proportions of the 
Salmonella I 4,[5],12:i:- isolates tested were resistant to ampicillin (6.1%), tetracycline, streptomycin, amoxicillin-
clavulanic acid, ceftiofur, and cefoxitin (3.0%). The prevalence of resistance among clinically important 
antimicrobial subclasses was 0.0% for quinolones (represented by nalidixic acid) and 1.7% for third-generation 
cephalosporins (represented by ceftiofur) (Table 1.20).
 
Ceftiofur resistance was first noted in one isolate (7.1%) in 2001; it decreased to 2.8% in 2004 and rose again to 
3.0% in 2005 (Table 1.18).  
 
Most Salmonella I 4,[5],12:i:-  isolates had no detected resistance.  In contrast to other common serotypes, the 
percentage of Salmonella I 4,[5],12:i:-  isolates with no detected resistance increased from 80.6% in 2004 to 
87.9% in 2005 (Table 1.19). In addition, resistance to at least three subclasses of antimicrobial agents decreased 
from 11.1% in 2004 to 3.0% in 2005. 
 
Multidrug-resistance was not common in Salmonella I 4,[5],12:i:- (Table 1.19). Resistance to at least ampicillin, 
chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, and tetracycline (ACSSuT) and resistance to at 
least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (ACSuTm) were first reported in 2001. 
 
 
Table 1.17: Minimum inhibitory concentrations (MICs) and resistance of Salmonella I 4,[5],12:i:- isolates to 
antimicrobial agents, 2005 (N=33) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–10.6] 9.1 75.8 15.2
Gentamicin 0.0 0.0 [0.0–10.6] 72.7 27.3
Streptomycin NA 3.0 [0.1–15.8] 97.0 3.0
Aminopenicillins Ampicillin 0.0 6.1 [0.7–20.2] 78.8 15.2 6.1
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.0 3.0 [0.1–15.8] 81.8 9.1 3.0 3.0 3.0
Ceftiofur 0.0 3.0 [0.1–15.8] 78.8 18.2 3.0
Ceftriaxone 3.0 0.0 [0.0–10.6] 97.0 3.0
Ciprofloxacin 0.0 0.0 [0.0–10.6] 100.0
Nalidixic Acid NA 0.0 [0.0–10.6] 60.6 36.4 3.0
Aminoglycosides Kanamycin 0.0 0.0 [0.0–10.6] 100.0
Cephamycins Cefoxitin 0.0 3.0 [0.1–15.8] 42.4 51.5 3.0 3.0
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.0 [0.0–10.6] 93.9 6.1
Phenicols Chloramphenicol 0.0 0.0 [0.0–10.6] 81.8 18.2
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 0.0 [0.0–10.6] 15.2 66.7 18.2
Tetracyclines Tetracycline 0.0 3.0 [0.1–15.8] 97.0 3.0
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides































Table 1.18: Percentage and number of Salmonella I 4,[5],12:i:- isolates resistant to antimicrobial agents, 
1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005




Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.0% 0.0% 7.1% 0.0% 5.4% 5.6% 0.0%
(MIC ≥ 16) 0 0 0 0 0 1 0 2 2 0
Streptomycin 0.0% 66.7% 0.0% 0.0% 7.7% 14.3% 2.9% 8.1% 5.6% 3.0%
(MIC ≥ 64) 0 2 0 0 1 2 1 3 2 1
Ampicillin 0.0% 0.0% 0.0% 0.0% 7.7% 7.1% 8.6% 8.1% 5.6% 6.1%
(MIC ≥ 32) 0 0 0 0 1 1 3 3 2 2
Amoxicillin-clavulanic acid 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 2.9% 5.4% 2.8% 3.0%
(MIC ≥ 32) 0 0 0 0 0 0 1 2 1 1
Ceftiofur 0.0% 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 5.4% 2.8% 3.0%
(MIC ≥ 8) 0 0 0 0 0 1 1 2 1 1
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 2.8% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 1 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic Acid 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 2.7% 2.8% 0.0%
(MIC ≥ 32) 0 0 0 0 0 0 0 1 1 0
Aminoglycosides Kanamycin 0.0% 0.0% 0.0% 0.0% 0.0% 7.1% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 1 0 0 0 0
Cephalothin 0.0% 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 5.4% Not Not
(MIC ≥ 32) 0 0 0 0 0 1 1 2 Tested Teste
Cefoxitin Not Not Not Not Not 0.0% 2.9% 5.4% 2.8% 3.0%
(MIC ≥ 32) Tested Tested Tested Tested Tested 0 1 2 1 1
Trimethoprim-sulfamethoxazole 0.0% 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0%
(MIC ≥ 4) 0 0 0 0 0 1 1 0 1 0
Chloramphenicol 0.0% 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0%
(MIC ≥ 32) 0 0 0 0 0 1 1 0 1 0
Sulfamethoxazole/Sulfisoxazole* 0.0% 100.0% 0.0% 12.5% 0.0% 14.3% 2.9% 5.4% 11.1% 0.0%
(MIC ≥ 512) 0 3 0 1 0 2 1 2 4 0
Tetracycline 0.0% 0.0% 0.0% 0.0% 7.7% 7.1% 5.7% 0.0% 11.1% 3.0%
(MIC ≥ 16) 0 0 0 0 1 1 2 0 4 1


















Table 1.19: Resistance patterns of Salmonella I 4,[5],12:i:- isolates, 1996–2005 
Year 1996 1997 1999 2000 2001 2002 2003 2004 2005
Total Isolates 3 3 8 13 14 35 37 36 33
% % % % % % % % %
n n n n n n n n n
No resistance detected 100.0% 0.0% 87.5% 92.3% 78.6% 91.4% 78.4% 80.6% 87.9%
 3 0 7 12 11 32 29 29 29
Resistance ≥1CLSI subclass* 0.0% 100.0% 12.5% 7.7% 21.4% 8.6% 21.6% 19.4% 12.1%
 0 3 1 1 3 3 8 7 4
Resistance ≥2 CLSI subclasses* 0.0% 66.7% 0.0% 7.7% 14.3% 8.6% 10.8% 13.9% 3.0%
 0 2 0 1 2 3 4 5 1
Resistance ≥3 CLSI subclasses* 0.0% 0.0% 0.0% 7.7% 7.1% 5.7% 5.4% 11.1% 3.0%
 0 0 0 1 1 2 2 4 1
Resistance ≥4 CLSI subclasses* 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0%
 0 0 0 0 1 1 0 1 0
Resistance ≥5 CLSI subclasses* 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0%
 0 0 0 0 1 1 0 1 0
At least ACSSuT† 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 2.8% 0.0%
 0 0 0 0 1 1 0 1 0
At least ACSuTm‡ 0.0% 0.0% 0.0% 0.0% 7.1% 2.9% 0.0% 0.0% 0.0%
 0 0 0 0 1 1 0 0 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)    
 
 
F. Specific Phenotypes 
 
The multidrug-resistant phenotypes ACSSuT and MDR-AmpC, and resistance to nalidixic acid and ceftiofur, were 
detected in several other serotypes in 2005 (Table 1.20). 
 
In 2005, 141 (6.9%) non-Typhi Salmonella isolates were resistant to at least ACSSuT. Of these isolates, 68.8% 
were serotype Typhimurium; 18.4% were Newport; and 2.8% were serotype Java [Paratyphi B var. L(+) tartrate+]; 
2.1% were serotype Agona; 1.4% were serotype Enteritidis, and 0.7% were serotype Mbandaka (Table 1.20). 
Forty-one (1.9%) non-Typhi Salmonella isolates were at least MDR-AmpC, of which 63.4% were serotype 
Newport, 19.5% Typhimurium; 7.3%, Agona; 2.4%, Enteritidis and 2.4%, Mbandaka. Fifty (2.4%) non-Typhi 
Salmonella isolates were nalidixic acid resistant, 36.0% of which were Enteritidis; 8.0%, Typhimurium; 4.0% 
Javiana, and 2.0%, Agona, Infantis, Heidelberg Muenchen, and Thompson. Sixty (2.9%) non-Typhi Salmonella 
isolates were ceftiofur resistant, of which 43.3% were serotype Newport; 18.3% were Typhimurium; 18.3% were 





Table 1.20: Number and percentage of ACSSuT-, MDR-AmpC-, nalidixic acid-, and ceftiofur-resistant 
isolates among the 20 most common non-Typhi Salmonella serotypes isolated in NARMS, 2005 
Rank Serotype N n (%) n (%) n (%) n (%)
1 Typhimurium 437 97 (68.8%) 8 (19.5%) 4 (8.0%) 11 (18.3%)
2 Enteritidis 383 2 (1.4%) 1 (2.4%) 18 (36.0%) 2 (3.3%)
3 Newport 207 26 (18.4%) 26 (63.4%) 0 (0.0%) 26 (43.3%)
4 Heidelberg 125 0 (0.0%) 0 (0.0%) 1 (2.0%) 11 (18.3%)
5 Javiana 75 0 (0.0%) 0 (0.0%) 2 (4.0%) 0 (0.0%)
6 Montevideo 48 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
7 Braenderup 47 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
8 Muenchen 44 0 (0.0%) 0 (0.0%) 1 (2.0%) 0 (0.0%)
9 Saintpaul 41 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
10 Paratyphi B var. L(+) tartrate+ 38 4 (2.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
11 Mississippi 37 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
12 I 4,[5],12:i:- (monophasic Typhimurium) 33 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.7%)
13 Oranienburg 33 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
14 Infantis 30 0 (0.0%) 0 (0.0%) 1 (2.0%) 0 (0.0%)
15 Thompson 26 0 (0.0%) 0 (0.0%) 1 (2.0%) 0 (0.0%)
16 Agona 22 3 (2.1%) 3 (7.3%) 1 (2.0%) 3 (5.0%)
17 Poona 19 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
18 Stanley 17 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
19 Mbandaka 17 1 (0.7%) 1 (2.4%) 0 (0.0%) 1 (1.7%)
20 Berta 13 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Subtotal 1692 133 (94.3%) 39 (95.1%) 29 (58.0%) 55 (91.7%)
All Other Serotypes 360 8 (5.7%) 2 (4.9%) 21 (42.0%) 5 (8.3%)
Total 2052 141 (100.0%) 41 (100.0%) 50 (100.0%) 60 (100.0%)
*ACSSuT: ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline
† MDR-AmpC: ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2µg/mL)





2. Salmonella Typhi 
 
Among Salmonella Typhi isolates, resistance to nalidixic acid increased from 19.2% in 1996 to 48.4% in 2005. 
Resistance increased from 2004 to 2005 to most of the antimicrobial agents tested.  The percentage of isolates 
with no detected resistance decreased from 56.6% in 2004 to 48.1% in 2005. 
 
During 2005, CDC received 418 Salmonella Typhi isolates, of which 382 (91.3%) were viable and tested for 
antimicrobial susceptibility; of these isolates, 64 (1.4%) were not included in the analysis because they were 
duplicate submissions from the same patient, leaving 318 isolates for analysis (Tables II and 2.01). Antimicrobial 
agents with the highest prevalence of resistance were nalidixic acid (48.4%), trimethoprim-sulfamethoxazole 
(14.2%), sulfisoxazole (14.2%), and chloramphenicol, streptomycin and ampicillin (13.2%). 
 
Resistance increased from 2004 to 2005 to most of the antimicrobial agents tested (Table 2.02).  Nalidixic acid 
resistance increased from 19.2% in 1999 to 48.4% in 2005; a statistically significant increase (OR=4.0, 95% CI 
[2.5, 6.3]). 
 
The percentage of isolates with no detected resistance decreased from 56.6% in 2004 to 48.1% in 2005.  In 1999, 
12.6% of Salmonella Typhi isolates were resistant to at least ampicillin, chloramphenicol, and trimethoprim-
sulfamethoxazole (ACSuTm), which increased to 15.6% in 2003 but declined to 12.9% in 2005 (Table 2.03).   
 
43 
Table 2.01: Minimum inhibitory concentrations (MICs) and resistance of Salmonella Typhi isolates to 
antimicrobial agents, 2005 (N=318) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.2] 34.9 57.9 6.3 0.9
Gentamicin 0.0 0.0 [0.0–1.2] 94.0 6.0
Streptomycin NA 13.2 [9.7–17.4] 86.8 13.2
Aminopenicillins Ampicillin 0.0 13.2 [9.7–17.4] 69.2 17.6 13.2
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.6 0.0 [0.0–1.2] 86.8 4.1 8.5 0.6
Ceftiofur 0.0 0.0 [0.0–1.2] 2.2 11.0 77.7 9.1
Ceftriaxone 0.0 0.0 [0.0–1.2] 100.0
Ciprofloxacin 0.0 0.3 [0.0–1.7] 48.4 1.3 2.2 15.7 29.6 2.5 0.3
Nalidixic Acid NA 48.4 [42.8–54.1] 1.3 43.1 5.3 1.9 0.6 47.8
Aminoglycosides Kanamycin 0.0 0.0 [0.0–1.2] 100.0
Cephamycins Cefoxitin 0.0 0.0 [0.0–1.2] 4.7 38.1 11.6 33.3 12.3
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 14.5 [10.8–18.8] 76.4 9.1 14.5
Phenicols Chloramphenicol 0.0 13.2 [9.7–17.4] 5.3 73.0 8.5 13.2
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 14.2 [10.5–18.5] 50.3 22.3 11.3 1.9 14.2
Tetracyclines Tetracycline 0.0 10.1 [7.0–13.9] 89.9 10.1
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides































Table 2.02: Percentage and number of Salmonella Typhi isolates resistant to antimicrobial agents, 1999–
2005
Year 1999 2000 2001 2002 2003 2004 2005




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 16) 0 0 0 0 0 0 0
Streptomycin 13.8% 9.0% 20.3% 7.2% 14.4% 11.8% 13.2%
(MIC ≥ 64) 23 16 40 14 48 36 42
Ampicillin 13.2% 9.0% 20.3% 5.6% 16.2% 11.8% 13.2%
(MIC ≥ 32) 22 16 40 11 54 36 42
Amoxicillin-clavulanic acid 0.6% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0%
(MIC ≥ 32) 1 0 0 0 1 0 0
Ceftiofur 0.6% 0.0% 0.0% 0.0% 0.6% 0.0% 0.0%
(MIC ≥ 8) 1 0 0 0 2 0 0
Ceftriaxone 0.6% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0%
(MIC ≥ 64) 1 0 0 0 1 0 0
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.3%
(MIC ≥ 4) 0 0 0 0 1 0 1
Nalidixic Acid 19.2% 22.0% 29.9% 23.6% 37.7% 41.8% 48.4%
(MIC ≥ 32) 32 39 59 46 126 127 154
Aminoglycosides Kanamycin 0.0% 0.0% 0.5% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 1 0 0 0 0
Cephalothin 2.4% 1.1% 0.5% 1.5% 0.6% Not Not
(MIC ≥ 32) 4 2 1 3 2 Tested Tested
Cefoxitin Not 0.6% 0.5% 0.0% 0.9% 0.0% 0.0%
(MIC ≥ 32) Tested 1 1 0 3 0 0
Trimethoprim-sulfamethoxazole 13.2% 9.0% 20.8% 6.7% 16.8% 13.2% 14.5%
(MIC ≥ 4) 22 16 41 13 56 40 46
Chloramphenicol 12.6% 10.7% 20.8% 6.2% 16.5% 13.2% 13.2%
(MIC ≥ 32) 21 19 41 12 55 40 42
Sulfamethoxazole/Sulfisoxazole* 16.8% 11.3% 20.8% 6.2% 17.1% 11.8% 14.2%
(MIC ≥ 512) 28 20 41 12 57 36 45
Tetracycline 9.6% 9.6% 20.8% 6.7% 15.6% 8.9% 10.1%
(MIC ≥ 16) 16 17 41 13 52 27 32















Table 2.03: Resistance patterns of Salmonella Typhi isolates, 1999–2005 
Year 1999 2000 2001 2002 2003 2004 2005
Total Isolates 167 177 197 195 334 304 318
% % % % % % %
n n n n n n n
No resistance detected 71.3% 72.9% 59.4% 74.4% 56.6% 56.6% 48.1%
 119 129 117 145 189 172 153
Resistance ≥1CLSI subclass* 28.7% 27.1% 40.6% 25.6% 43.4% 43.4% 51.9%
 48 48 80 50 145 132 165
Resistance ≥2 CLSI subclasses* 15.0% 10.7% 22.8% 7.2% 18.0% 13.2% 14.5%
 25 19 45 14 60 40 46
Resistance ≥3 CLSI subclasses* 13.2% 9.6% 22.8% 6.7% 17.7% 12.8% 13.8%
 22 17 45 13 59 39 44
Resistance ≥4 CLSI subclasses* 13.2% 9.0% 21.8% 6.7% 16.8% 12.5% 12.9%
 22 16 43 13 56 38 41
Resistance ≥5 CLSI subclasses* 12.6% 9.0% 18.8% 5.6% 15.9% 11.8% 11.9%
 21 16 37 11 53 36 38
At least ACSSuT† 9.6% 7.9% 16.8% 5.6% 12.6% 7.9% 9.1%
 16 14 33 11 42 24 29
At least ACSuTm‡ 12.6% 9.0% 17.8% 5.6% 15.6% 11.8% 12.9%
 21 16 35 11 52 36 41
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.3% 0.0% 0.0%
 0 0 0 0 1 0 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 





There were differences in resistance to antimicrobial agents between Shigella sonnei and Shigella flexneri.  In 
2005, Shigella sonnei isolates showed a higher prevalence of resistance to streptomycin and trimethoprim-
sulfamethoxazole, while S. flexneri showed a higher prevalence of resistance to tetracycline and chloramphenicol.  
The percentage of isolates with no detected resistance was low in  S. sonnei (4.4%) and S. flexneri (5.8%). 
 
During 2005, CDC received 436 Shigella isolates, of which 398 (91.3%) were viable and tested for antimicrobial 
susceptibility; two (0.5%) isolates were determined to be duplicate submissions from the same patient and were 
removed from analysis, leaving 396 (90.8%) isolates for analysis (Table II). Of the 396 isolates tested, 340 
(85.9%) were S. sonnei; 52 (13.1%), S. flexneri; three (0.8%), S. boydii; and one (0.3%), S. dysenteriae (Table 
3.01). Resistance was highest to ampicillin (70.7%), streptomycin (68.7%), trimethoprim-sulfamethoxazole 
(58.6%), sulfisoxazole (57.6%), and tetracycline (38.4%) (Table 3.02). 
 
In 2005, there were differences in resistance to antimicrobial agents between Shigella sonnei and Shigella flexneri 
(Tables 3.03 and 3.04).  Shigella sonnei isolates showed a higher prevalence of resistance to streptomycin and 
trimethoprim-sulfamethoxazole than Shigella flexneri: 70.3% streptomycin resistance in S. sonnei, compared with 
57.7% in S. flexneri; 61.2% trimethoprim-sulfamethoxazole resistance in S.sonnei, compared with 44.2% in S. 
flexneri.  However, S. flexneri showed a higher prevalence of resistance to tetracycline and chloramphenicol than 
S. sonnei:  94.2% tetracycline resistance in S. flexneri, compared with 29.4% in S. sonnei; 65.4% 
chloramphenicol resistance in S. flexneri, compared with 2.4% in S. sonnei. 
 
The percentage of S. sonnei isolates resistant to trimethoprim-sulfamethoxazole increased from 53.1% in 2004 to 
61.2% in 2005 (Tables 3.05 and 3.06), a rate similar to that during 1999–2000 (53.1–54.9%). Ampicillin resistance 
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among S. sonnei isolates remained high (70.3%). Tetracycline resistance also decreased from 36.1% in 2004 to 
29.4% in 2005. Two S. sonnei isolates were resistant to ceftriaxone in 2005 and one in 2004; these are the first 
three ceftriaxone-resistant Shigella isolates detected since NARMS began testing Shigella in 1999. 
 
Resistance of S. flexneri isolates to trimethoprim-sulfamethoxazole also increased from 28.8% in 2002 to 44.2% 
in 2005 (Tables 3.05 and 3.07). Nalidixic acid resistance was 1.6% in 2004, compared with 3.8% in 2005. 
Resistance to streptomycin and tetracycline was higher in 2004 (72.1% and 95.1%, respectively) than in 2005 
(57.7% and 94.2%, respectively).  
 
Among all Shigella spp. isolates tested in all years from 1999 to 2005, more than 90% of isolates, which ranged 
from 90.9% to 95.6%, were resistant to at least one CLSI subclass. However, resistance to at least five CLSI 
subclasses declined from 1999 to 2005:  40.5% were resistant to at least five subclasses in 1999, compared with 
15.7% in 2005 (Table 3.08).   
 
In all years from 1999 to 2005, resistance to at least ampicilin, chloramphenicol, streptomycin, 
sulfamethoxazole/sulfisoxazole, and tetracycline (ACSSuT) and resistance to at least ampicillin, chloramphenicol, 
and trimethoprim-sulfamethoxazole (ACSuTm) were higher in S. flexneri compared with S. sonnei (Tables 3.09 
and 3.10).  The percentage of isolates with no detected resistance among S. sonnei and S. flexneri remained low 
in all years from 1999 to 2005; it was 4.4% in S. sonnei and 5.8% in S. flexneri  in 2005. 
 
For both S. sonnei and S. flexneri, resistance to clinically important antimicrobial classes and specific 
combinations changed from 1999 to 2005 (Tables 3.09 and 3.10). One Shigella (S. sonnei) isolate was resistant 
to nalidixic acid and ceftiofur. This was the second S. sonnei isolate with this phenotype reported in NARMS. The 
first reported Shigella isolate with this phenotype in NARMS was a S. flexneri isolated in 2003. Combined 
resistance to ampicillin and trimethoprim-sulfamethoxazole was present in more than 40% of isolates from 1999 
through 2001, declined to 30.2% in 2002, but increased to 39.4% in 2004 and 40.6% in 2005. Resistance to both 




Table 3.01: Frequency of Shigella species isolated in NARMS, 2005 
N (%)
Shigella sonnei 340 (85.9%)
Shigella flexneri 52 (13.1%)
Shigella boydii 3 (0.8%)








Table 3.02: Minimum inhibitory concentrations (MICs) and resistance of Shigella isolates to antimicrobial 
agents, 2005 (N=396) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.3 0.0 [0.0–0.9] 0.3 5.3 51.5 39.6 3.0 0.3
Gentamicin 0.0 1.0 [0.3–2.6] 2.3 32.1 61.1 3.3 0.3 1.0
Streptomycin NA 68.7 [63.9–73.2] 31.3 37.4 31.3
Aminopenicillins Ampicillin 0.8 70.7 [66.0–75.1] 4.5 18.9 4.5 0.5 0.8 1.3 69.4
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 16.9 1.0 [0.3–2.6] 1.8 5.3 22.0 53.0 16.9 1.0
Ceftiofur 0.0 0.5 [0.1–1.8] 15.2 76.3 6.6 1.5 0.5
Ceftriaxone 0.0 0.5 [0.1–1.8] 99.0 0.5 0.5
Ciprofloxacin 0.0 0.0 [0.0–0.9] 98.2 0.5 1.0 0.3
Nalidixic Acid NA 1.5 [0.6–3.3] 0.8 72.2 24.0 1.5 0.5 1.0
Aminoglycosides Kanamycin 0.0 0.8 [0.2–2.2] 98.2 1.0 0.8
Cephamycins Cefoxitin 0.8 0.3 [0.0–1.4] 17.9 68.9 11.9 0.3 0.8 0.3
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 58.6 [53.6–63.5] 24.2 5.1 2.0 4.0 6.1 4.3 54.3
Phenicols Chloramphenicol 10.6 10.9 [8.0–14.3] 10.9 56.8 10.9 10.6 1.5 9.3
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 57.6 [52.5–62.5] 39.1 2.8 0.5 57.6
Tetracyclines Tetracycline 0.3 38.4 [33.6–43.4] 61.4 0.3 2.5 11.9 24.0
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides
































Table 3.03: Minimum inhibitory concentrations (MICs) and resistance of Shigella sonnei isolates to 
antimicrobial agents, 2005 (N=340) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.1] 0.3 5.9 56.8 36.2 0.9
Gentamicin 0.0 1.2 [0.3–3.0] 2.1 34.4 60.3 2.1 1.2
Streptomycin NA 70.3 [65.1–75.1] 29.7 40.3 30.0
Aminopenicillins Ampicillin 0.9 70.6 [65.4–75.4] 1.8 20.9 5.3 0.6 0.9 1.5 69.1
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 9.7 1.2 [0.3–3.0] 0.9 3.5 24.1 60.6 9.7 1.2
Ceftiofur 0.0 0.6 [0.1–2.1] 11.5 80.0 6.5 1.5 0.6
Ceftriaxone 0.0 0.6 [0.1–2.1] 98.8 0.6 0.6
Ciprofloxacin 0.0 0.0 [0.0–1.1] 98.5 0.3 1.2
Nalidixic Acid NA 1.2 [0.3–3.0] 0.9 74.7 21.8 1.5 0.3 0.9
Aminoglycosides Kanamycin 0.0 0.0 [0.0–1.1] 98.8 1.2
Cephamycins Cefoxitin 0.9 0.3 [0.0–1.6] 19.7 71.5 7.6 0.9 0.3
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 61.2 [55.8–66.4] 22.1 4.1 0.9 4.7 7.1 5.0 56.2
Phenicols Chloramphenicol 12.4 2.4 [1.0–4.6] 7.1 65.6 12.6 12.4 0.9 1.5
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 57.9 [52.5–63.2] 38.2 3.2 0.6 57.9
Tetracyclines Tetracycline 0.3 29.4 [24.6–34.6] 70.3 0.3 2.4 12.6 14.4
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides


























Table 3:04: Minimum inhibitory concentrations and resistance of Shigella flexneri isolates to antimicrobial 
agents, 2005 (N=52) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 1.9 0.0 [0.0–6.8] 1.9 19.2 59.6 17.3 1.9
Gentamicin 0.0 0.0 [0.0–6.8] 3.8 19.2 63.5 11.5 1.9
Streptomycin NA 57.7 [43.2–71.3] 42.3 19.2 38.5
Aminopenicillins Ampicillin 0.0 75.0 [61.1–86.0] 21.2 3.8 75.0
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 65.4 0.0 [0.0–6.8] 5.8 17.3 3.8 7.7 65.4
Ceftiofur 0.0 0.0 [0.0–6.8] 36.5 55.8 5.8 1.9
Ceftriaxone 0.0 0.0 [0.0–6.8] 100.0
Ciprofloxacin 0.0 0.0 [0.0–6.8] 96.2 1.9 1.9
Nalidixic Acid NA 3.8 [0.5–13.2] 55.8 38.5 1.9 1.9 1.9
Aminoglycosides Kanamycin 0.0 3.8 [0.5–13.2] 96.2 3.8
Cephamycins Cefoxitin 0.0 0.0 [0.0–6.8] 5.8 53.8 38.5 1.9
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 44.2 [30.5–58.7] 38.5 9.6 7.7 44.2
Phenicols Chloramphenicol 0.0 65.4 [50.9–78.0] 30.8 3.8 5.8 59.6
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 55.8 [41.3–69.5] 44.2 55.8
Tetracyclines Tetracycline 0.0 94.2 [84.1–98.8] 5.8 1.9 7.7 84.6
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides


























Table 3.05: Percentage and number of Shigella isolates resistant to antimicrobial agents, 1999–2005 
Year 1999 2000 2001 2002 2003 2004 2005




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0
Gentamicin 0.3% 0.2% 0.0% 0.2% 0.0% 0.0% 1.0%
(MIC ≥ 16) 1 1 0 1 0 0 4
Streptomycin 55.7% 57.1% 53.2% 54.4% 57.0% 61.0% 68.7%
(MIC ≥ 64) 209 257 183 337 282 192 272
Ampicillin 77.6% 79.1% 79.7% 76.6% 79.4% 77.8% 70.7%
(MIC ≥ 32) 291 356 274 475 393 245 280
Amoxicillin-clavulanic acid 1.1% 2.2% 4.4% 2.6% 1.4% 1.6% 1.0%
(MIC ≥ 32) 4 10 15 16 7 5 4
Ceftiofur 0.0% 0.0% 0.0% 0.2% 0.2% 0.3% 0.5%
(MIC ≥ 8) 0 0 0 1 1 1 2
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.5%
(MIC ≥ 64) 0 0 0 0 0 1 2
Ciprofloxacin 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 1 0 0 0 0
Nalidixic Acid 1.6% 0.9% 1.7% 1.6% 1.0% 1.6% 1.5%
(MIC ≥ 32) 6 4 6 10 5 5 6
Aminoglycosides Kanamycin 0.5% 1.3% 0.6% 0.8% 0.4% 0.0% 0.8%
(MIC ≥ 64) 2 6 2 5 2 0 3
Cephalothin 3.2% 8.0% 9.0% 6.6% 9.3% Not Not
(MIC ≥ 32) 12 36 31 41 46 Tested Test
Cefoxitin Not 0.2% 1.2% 0.3% 0.0% 0.3% 0.3%
(MIC ≥ 32) Tested 1 4 2 0 1 1
Trimethoprim-sulfamethoxazole 51.5% 52.9% 46.8% 37.3% 38.6% 51.4% 58.6%
(MIC ≥ 4) 193 238 161 231 191 162 232
Chloramphenicol 17.3% 14.0% 21.5% 7.6% 8.5% 14.9% 10.9%
(MIC ≥ 32) 65 63 74 47 42 47 43
Sulfamethoxazole/Sulfisoxazole* 56.0% 55.8% 56.4% 31.8% 33.9% 52.4% 57.6%
(MIC ≥ 512) 210 251 194 197 168 165 228
Tetracycline 57.3% 44.9% 59.3% 30.6% 29.1% 49.2% 38.4%
(MIC ≥ 16) 215 202 204 190 144 155 152














Table 3.06: Percentage and number of Shigella sonnei isolates resistant to antimicrobial agents, 1999–
2005 
Year 1999 2000 2001 2002 2003 2004 2005




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0
Gentamicin 0.4% 0.3% 0.0% 0.0% 0.0% 0.0% 1.2%
(MIC ≥ 16) 1 1 0 0 0 0 4
Streptomycin 52.0% 56.0% 54.0% 55.4% 56.5% 58.1% 70.3%
(MIC ≥ 64) 143 205 129 297 245 140 239
Ampicillin 79.6% 80.6% 82.8% 77.6% 79.7% 79.3% 70.6%
(MIC ≥ 32) 219 295 198 416 346 191 240
Amoxicillin-clavulanic acid 0.4% 1.9% 4.6% 2.2% 1.4% 1.7% 1.2%
(MIC ≥ 32) 1 7 11 12 6 4 4
Ceftiofur 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.6%
(MIC ≥ 8) 0 0 0 0 0 1 2
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.6%
(MIC ≥ 64) 0 0 0 0 0 1 2
Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0
Nalidixic Acid 1.5% 1.1% 0.8% 1.5% 0.5% 1.7% 1.2%
(MIC ≥ 32) 4 4 2 8 2 4 4
Aminoglycosides Kanamycin 0.7% 1.6% 0.4% 0.4% 0.0% 0.0% 0.0%
(MIC ≥ 64) 2 6 1 2 0 0 0
Cephalothin 2.9% 8.7% 12.6% 7.3% 10.1% Not Not
(MIC ≥ 32) 8 32 30 39 44 Tested Tested
Cefoxitin Not 0.3% 1.7% 0.4% 0.0% 0.4% 0.3%
(MIC ≥ 32) Tested 1 4 2 0 1 1
Trimethoprim-sulfamethoxazole 53.1% 54.9% 50.6% 37.9% 38.5% 53.1% 61.2%
(MIC ≥ 4) 146 201 121 203 167 128 208
Chloramphenicol 1.8% 2.7% 1.3% 0.2% 1.2% 2.5% 2.4%
(MIC ≥ 32) 5 10 3 1 5 6 8
Sulfamethoxazole/Sulfisoxazole* 54.5% 56.0% 54.4% 29.9% 31.3% 49.0% 57.9%
(MIC ≥ 512) 150 205 130 160 136 118 197
Tetracycline 46.2% 34.4% 44.8% 23.5% 22.1% 36.1% 29.4%
(MIC ≥ 16) 127 126 107 126 96 87 100














Table 3.07: Percentage and number of Shigella flexneri isolates resistant to antimicrobial agents, 1999–
2005 
Year 1999 2000 2001 2002 2003 2004 2005




Amikacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 1.4% 0.0% 0.0% 0.0%
(MIC ≥ 16) 0 0 0 1 0 0 0
Streptomycin 63.2% 61.3% 47.3% 43.8% 60.8% 72.1% 57.7%
(MIC ≥ 64) 55 46 43 32 31 44 30
Ampicillin 77.0% 77.3% 72.5% 75.3% 84.3% 82.0% 75.0%
(MIC ≥ 32) 67 58 66 55 43 50 39
Amoxicillin-clavulanic acid 3.4% 4.0% 4.4% 5.5% 2.0% 1.6% 0.0%
(MIC ≥ 32) 3 3 4 4 1 1 0
Ceftiofur 0.0% 0.0% 0.0% 1.4% 2.0% 0.0% 0.0%
(MIC ≥ 8) 0 0 0 1 1 0 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0
Ciprofloxacin 0.0% 0.0% 1.1% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 1 0 0 0 0
Nalidixic Acid 1.1% 0.0% 3.3% 2.7% 5.9% 1.6% 3.8%
(MIC ≥ 32) 1 0 3 2 3 1 2
Aminoglycosides Kanamycin 0.0% 0.0% 1.1% 4.1% 3.9% 0.0% 3.8%
(MIC ≥ 64) 0 0 1 3 2 0 2
Cephalothin 4.6% 2.7% 1.1% 2.7% 3.9% Not Not
(MIC ≥ 32) 4 2 1 2 2 Tested Test
Cefoxitin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 32) Tested 0 0 0 0 0 0
Trimethoprim-sulfamethoxazole 48.3% 42.7% 34.1% 28.8% 39.2% 45.9% 44.2%
(MIC ≥ 4) 42 32 31 21 20 28 23
Chloramphenicol 64.4% 69.3% 74.7% 63.0% 68.6% 60.7% 65.4%
(MIC ≥ 32) 56 52 68 46 35 37 34
Sulfamethoxazole/Sulfisoxazole* 58.6% 53.3% 57.1% 41.1% 52.9% 65.6% 55.8%
(MIC ≥ 512) 51 40 52 30 27 40 29
Tetracycline 92.0% 92.0% 94.5% 78.1% 82.4% 95.1% 94.2%
(MIC ≥ 16) 80 69 86 57 42 58 49
















Table 3.08: Resistance patterns of Shigella isolates, 1999–2005 
Year 1999 2000 2001 2002 2003 2004 2005
Total Isolates 375 450 344 620 495 315 396
% % % % % % %
n n n n n n n
No resistance detected 9.1% 7.3% 4.9% 8.2% 8.5% 4.4% 4.5%
 34 33 17 51 42 14 18
Resistance ≥1CLSI subclass* 90.9% 92.7% 95.1% 91.8% 91.5% 95.6% 95.5%
 341 417 327 569 453 301 378
Resistance ≥2 CLSI subclasses* 63.7% 64.7% 69.8% 55.3% 57.8% 66.7% 73.7%
 239 291 240 343 286 210 292
Resistance ≥3 CLSI subclasses* 61.1% 62.0% 61.3% 41.8% 41.4% 62.2% 62.9%
 229 279 211 259 205 196 249
Resistance ≥4 CLSI subclasses* 54.1% 56.7% 54.1% 31.0% 32.5% 52.1% 55.6%
 203 255 186 192 161 164 220
Resistance ≥5 CLSI subclasses* 40.5% 26.2% 36.0% 20.5% 22.4% 27.6% 15.7%
 152 118 124 127 111 87 62
At least ACSSuT† 8.5% 5.6% 6.4% 1.8% 3.2% 6.0% 4.0%
 32 25 22 11 16 19 16
At least ACSuTm‡ 9.9% 6.9% 7.0% 2.7% 3.6% 6.7% 6.3%
 37 31 24 17 18 21 25
At least ASuTm§ 44.3% 44.4% 37.5% 29.8% 33.7% 37.8% 39.9%
 166 200 129 185 167 119 158
At least ANSuTm¶ 0.3% 0.0% 0.6% 0.3% 0.8% 0.6% 0.5%
 1 0 2 2 4 2 2
At least ACSSuTAuCf** 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.2% 0.3% 0.3%
 0 0 0 0 1 1 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ASuTm: resistance to ampicillin, trimethoprim-sulfamethoxazole
¶ANSuTm: resistance to ASuTm + naladixic acid
**ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
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Table 3.09: Resistance patterns of Shigella sonnei isolates, 1999–2005 
Year 1999 2000 2001 2002 2003 2004 2005
Total Isolates 275 366 239 536 434 241 340
% % % % % % %
n n n n n n n
No resistance detected 10.5% 7.7% 5.4% 7.1% 8.5% 5.0% 4.4%
 29 28 13 38 37 12 15
Resistance ≥1CLSI subclass* 89.5% 92.3% 94.6% 92.9% 91.5% 95.0% 95.6%
 246 338 226 498 397 229 325
Resistance ≥2 CLSI subclasses* 56.0% 60.7% 60.7% 52.1% 54.1% 59.8% 72.6%
 154 222 145 279 235 144 247
Resistance ≥3 CLSI subclasses* 54.5% 57.7% 53.1% 36.6% 36.2% 54.4% 60.0%
 150 211 127 196 157 131 204
Resistance ≥4 CLSI subclasses* 50.5% 54.1% 49.0% 26.7% 28.6% 46.5% 53.5%
 139 198 117 143 124 112 182
Resistance ≥5 CLSI subclasses* 38.5% 23.5% 36.0% 19.4% 20.0% 24.9% 11.5%
 106 86 86 104 87 60 39
At least ACSSuT† 0.4% 0.8% 0.0% 0.0% 0.2% 0.0% 0.3%
 1 3 0 0 1 0 1
At least ACSuTm‡ 1.8% 1.9% 0.8% 0.2% 0.9% 1.7% 2.4%
 5 7 2 1 4 4 8
At least ASuTm§ 45.1% 46.2% 41.0% 30.2% 33.6% 39.4% 40.6%
 124 169 98 162 146 95 138
At least ANSuTm¶ 0.0% 0.0% 0.0% 0.2% 0.2% 0.8% 0.3%
 0 0 0 1 1 2 1
At least ACSSuTAuCf** 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.3%
 0 0 0 0 0 1 1
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ASuTm: resistance to ampicillin, trimethoprim-sulfamethoxazole
¶ANSuTm: resistance to ASuTm + naladixic acid
**ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
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Table 3.10: Resistance patterns of Shigella flexneri isolates, 1999–2005 
Year 1999 2000 2001 2002 2003 2004 2005
Total Isolates 87 75 91 73 51 61 52
% % % % % % %
n n n n n n n
No resistance detected 4.6% 4.0% 3.3% 15.1% 7.8% 0.0% 5.8%
 4 3 3 11 4 0 3
Resistance ≥1CLSI subclass* 95.4% 96.0% 96.7% 84.9% 92.2% 100.0% 94.2%
 83 72 88 62 47 61 49
Resistance ≥2 CLSI subclasses* 83.9% 82.7% 90.1% 76.7% 86.3% 93.4% 80.8%
 73 62 82 56 44 57 42
Resistance ≥3 CLSI subclasses* 80.5% 81.3% 80.2% 75.3% 82.4% 91.8% 80.8%
 70 61 73 55 42 56 42
Resistance ≥4 CLSI subclasses* 67.8% 69.3% 65.9% 58.9% 64.7% 75.4% 69.2%
 59 52 60 43 33 46 36
Resistance ≥5 CLSI subclasses* 49.4% 40.0% 31.9% 28.8% 45.1% 41.0% 44.2%
 43 30 29 21 23 25 23
At least ACSSuT† 33.3% 29.3% 22.0% 15.1% 29.4% 27.9% 28.8%
 29 22 20 11 15 17 15
At least ACSuTm‡ 34.5% 32.0% 23.1% 21.9% 27.5% 24.6% 32.7%
 30 24 21 16 14 15 17
At least ASuTm§ 44.8% 38.7% 25.3% 27.4% 37.3% 36.1% 38.5%
 39 29 23 20 19 22 20
At least ANSuTm¶ 1.1% 0.0% 1.1% 1.4% 5.9% 0.0% 1.9%
 1 0 1 1 3 0 1
At least ACSSuTAuCf** 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0
At least MDR-AmpC†† 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 2.0% 0.0% 0.0%
 0 0 0 0 1 0 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ASuTm: resistance to ampicillin, trimethoprim-sulfamethoxazole
¶ANSuTm: resistance to ASuTm + naladixic acid
**ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
††MDR-AmpC: resistance to ACSSuTAuCf + decreased susceptibility to ceftriaxone (MIC ≥2 µg/mL)   
 
 
4. Escherichia coli O157 
 
In E. coli O157, resistance to antimicrobial agents was not common.  From 1996 to 2005, there was no temporal 
trend in the percentage of isolates with no detected resistance, which ranged from 86.6% to 95.3%.  Multidrug 
resistance was rare. 
 
In 2005, CDC received a total of 214 Escherichia coli O157 isolates, of which 194 (90.7%) were viable and tested 
for antimicrobial susceptibility (Table II). Resistance to antimicrobial agents was not common.  Antimicrobial 
agents with the highest prevalence of resistance were tetracycline (8.8%), sulfisoxazole (6.7%), ampicillin (4.1%), 
and streptomycin (2.1%). Ampicillin resistance decreased from 3.2% in 2003 to 1.2% in 2004 but increased again 
in 2005 to 4.1% (Table 4.01). Cefoxitin resistance decreased to 0.0% in 2005, down from 0.6% in 2004. No 
isolates in 2005 were resistant to ceftiofur, whereas two isolates were resistant in 2003 (Table 4.02). 
 
Isolates resistant to at least one CLSI subclass increased from 4.7% in 2004 to 12.4% in 2005 (Table 4.03). 
Resistance to at least two CLSI subclasses increased from 1.2% in 2004 to 5.2% in 2005. No isolates were 
resistant to at least five subclasses in 2005.  From 1996 to 2005, there was no temporal trend in the percentage 
of isolates with no detected resistance, which ranged from 86.6% to 95.3%.  Multidrug resistance was rare. 
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Antimicrobial treatment of E. coli O157 infections is not recommended. However, third-generation cephalosporin 
resistance surveillance might prove useful in understanding resistance mechanisms and the exchange of mobile 
resistance elements among enteric pathogens in bovine production settings.
 
Table 4.01: Minimum inhibitory concentrations (MICs) and resistance of Escherichia coli O157 isolates to 
antimicrobial agents, 2005 (N=194) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–1.9] 5.2 73.2 19.1 2.6
Gentamicin 0.0 0.5 [0.0–2.8] 54.6 42.8 2.1 0.5
Streptomycin NA 2.1 [0.6–5.2] 97.9 1.0 1.0
Aminopenicillins Ampicillin 0.0 4.1 [1.8–8.0] 4.6 72.7 17.0 1.5 4.1
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 0.5 0.0 [0.0–1.9] 0.5 9.3 86.1 3.6 0.5
Ceftiofur 0.0 0.0 [0.0–1.9] 3.1 30.9 63.4 2.6
Ceftriaxone 0.0 0.0 [0.0–1.9] 100.0
Ciprofloxacin 0.0 0.0 [0.0–1.9] 97.9 0.5 0.5 1.0
Nalidixic Acid NA 1.5 [0.3–4.5] 0.5 2.6 77.3 18.0 1.5
Aminoglycosides Kanamycin 0.0 0.5 [0.0–2.8] 99.5 0.5
Cephamycins Cefoxitin 1.0 0.0 [0.0–1.9] 2.1 7.7 75.3 13.9 1.0
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 0.5 [0.0–2.8] 95.9 3.6 0.5
Phenicols Chloramphenicol 0.5 1.0 [0.1–3.7] 4.6 31.4 62.4 0.5 1.0
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 6.7 [3.6–11.2] 87.1 5.7 0.5 6.7
Tetracyclines Tetracycline 1.0 8.8 [5.2–13.7] 90.2 1.0 1.0 0.5 7.2
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints 
for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested 
concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides



























Table 4.02: Percentage and number of Escherichia coli O157 isolates resistant to antimicrobial agents, 
1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005




Aminoglycosides Amikacin Not 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) Tested 0 0 0 0 0 0 0 0 0
Gentamicin 0.0% 0.0% 0.0% 0.3% 0.5% 0.4% 0.0% 0.0% 0.6% 0.5%
(MIC ≥ 16) 0 0 0 1 2 1 0 0 1 1
Streptomycin 2.0% 2.5% 1.9% 2.7% 5.2% 1.8% 2.3% 1.9% 1.8% 2.1%
(MIC ≥ 64) 4 4 6 8 21 5 9 3 3 4
Aminopenicillins Ampicillin 1.5% 0.0% 2.5% 1.4% 2.7% 2.2% 1.5% 3.2% 1.2% 4.1%
(MIC ≥ 32) 3 0 8 4 11 6 6 5 2 8
Beta-lactamase inhibitor combinations Amoxicillin-clavulanic acid 0.0% 0.0% 0.0% 0.3% 1.0% 0.7% 0.0% 1.3% 0.0% 0.0%
(MIC ≥ 32) 0 0 0 1 4 2 0 2 0 0
Ceftiofur 0.0% 0.0% 0.0% 0.0% 1.0% 1.1% 0.0% 1.3% 0.0% 0.0%
(MIC ≥ 8) 0 0 0 0 4 3 0 2 0 0
Ceftriaxone 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 64) 0 0 0 0 0 0 0 0 0 0
Quinolones Ciprofloxacin 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
(MIC ≥ 4) 0 0 0 0 0 0 0 0 0 0
Nalidixic acid 0.0% 0.0% 0.0% 0.7% 0.5% 1.1% 1.0% 0.6% 1.8% 1.5%
(MIC ≥ 32) 0 0 0 2 2 3 4 1 3 3
Aminoglycosides Kanamycin 0.0% 0.0% 0.3% 0.7% 1.0% 0.0% 0.5% 0.0% 0.0% 0.5%
(MIC ≥ 64) 0 0 1 2 4 0 2 0 0 1
Cephalothin 1.5% 2.5% 0.0% 0.7% 1.2% 1.4% 1.5% 2.5% Not Not
(MIC ≥ 32) 3 4 0 2 5 4 6 4 Tested Teste
Cephamycins Cefoxitin Not Not Not Not 1.0% 0.7% 0.0% 1.3% 0.6% 0.0%
(MIC ≥ 32) Tested Tested Tested Tested 4 2 0 2 1 0
Folate pathway inhibitors Trimethoprim-sulfamethoxazole 0.0% 0.0% 0.6% 1.4% 0.7% 0.7% 0.5% 0.6% 0.0% 0.5%
(MIC ≥ 4) 0 0 2 4 3 2 2 1 0 1
Phenicols Chloramphenicol 0.5% 0.0% 0.3% 0.0% 3.7% 1.4% 1.3% 1.3% 0.6% 1.0%
(MIC ≥ 32) 1 0 1 0 15 4 5 2 1 2
Sulfonamides Sulfamethoxazole/Sulfisoxazole* 11.9% 9.9% 5.7% 8.2% 5.9% 5.1% 3.5% 3.8% 1.8% 6.7%
(MIC ≥ 512) 24 16 18 24 24 14 14 6 3 13
Tetracyclines Tetracycline 5.0% 3.1% 4.4% 3.4% 7.1% 5.4% 3.0% 5.7% 1.8% 8.8%
(MIC ≥ 16) 10 5 14 10 29 15 12 9 3 17







Table 4.03: Resistance patterns of Escherichia coli O157 isolates, 1996–2005 
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Total Isolates 201 161 318 292 407 277 399 157 169 194
% % % % % % % % % %
n n n n n n n n n n
No resistance detected 86.6% 88.8% 92.8% 89.7% 90.4% 91.3% 94.0% 90.4% 95.3% 87.6%
 174 143 295 262 368 253 375 142 161 170
Resistance ≥1CLSI subclass* 13.4% 11.2% 7.2% 10.3% 9.6% 8.7% 6.0% 9.6% 4.7% 12.4%
 27 18 23 30 39 24 24 15 8 24
Resistance ≥2 CLSI subclasses* 5.0% 3.7% 5.3% 3.4% 6.6% 5.4% 3.8% 5.1% 1.2% 5.2%
 10 6 17 10 27 15 15 8 2 10
Resistance ≥3 CLSI subclasses* 1.5% 0.6% 1.9% 3.1% 4.7% 2.2% 2.0% 3.2% 0.6% 1.0%
 3 1 6 9 19 6 8 5 1 2
Resistance ≥4 CLSI subclasses* 0.5% 0.0% 0.9% 1.0% 3.7% 1.8% 1.0% 1.3% 0.6% 0.5%
 1 0 3 3 15 5 4 2 1 1
Resistance ≥5 CLSI subclasses* 0.5% 0.0% 0.0% 0.7% 1.5% 0.7% 0.3% 0.6% 0.0% 0.0%
 1 0 0 2 6 2 1 1 0 0
At least ACSSuT† 0.5% 0.0% 0.0% 0.0% 1.2% 0.4% 0.0% 0.0% 0.0% 0.0%
 1 0 0 0 5 1 0 0 0 0
At least ACSuTm‡ 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 1 0 0 0 0 0
At least ACSSuTAuCf§ 0.0% 0.0% 0.0% 0.0% 1.0% 0.4% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 4 1 0 0 0 0
At least MDR-AmpC¶ 0.0% 0.0% 0.0% 0.0% 1.0% 0.4% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 4 1 0 0 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 






Among all Campylobacter isolates tested, ciprofloxacin resistance increased from 12.9% in 1997 to 21.7 in 2005.   
Resistance to erythromycin remained low during 1997 to 2005. An increase in ciprofloxacin resistance in C. jejuni 
similar to the trend in all Campylobacter isolates was observed. The percentage of resistance to most agents 
tested, including ciprofloxacin and erythromycin, was higher in C. coli compared with C. jejuni.  
 
In 2005, CDC received 998 Campylobacter isolates, of which 890 (89.2%) were viable and tested for antimicrobial 
susceptibility. A total of 791 (92.6%) were C. jejuni and 98 (11.5%) were C. coli (Table 5.01). 
 
Of the Campylobacter isolates tested in 2005 (Table II), resistance was highest to tetracycline (40.6%), nalidixic 
acid (22.4%), and ciprofloxacin (21.7%) (Table 5.02). Of the isolates tested, 0.6% were resistant to florfenicol, 
which replaced chloramphenicol to represent the phenicol antimicrobial subclass. 
 
The percentage of Campylobacter isolates resistant to ciprofloxacin increased from 12.9% in 1997 to 21.7% in 
2005, which is a statistically significant increase (OR=2.2, 95% CI [1.4, 3.4]).   Resistance to erythromycin 
remained low at 2.1% or less during 1997 to 2005.  It increased from 0.3% in 2004 to 1.8% in 2005 (Table 5.03). 
 
In 2005, 51.6% of Campylobacter isolates were resistant to one or more CLSI subclass, compared with 53.9% in 
2004 (Table 5.04). In 2005, 13.6% of Campylobacter isolates were resistant to two or more subclasses, compared 
with 14.1% in 2004. 
 
In 2005, the antimicrobial agent with the highest prevalence of resistance among the 791 C. jejuni isolates was 
tetracycline (41.8), followed by nalidixic acid (21.9%) and ciprofloxacin (21.5%) (Table 5.05). Of note, 0.5% and 
1.6% of C. jejuni isolates were resistant to gentamicin and erythromycin, respectively. 
 
The percentage of C. jejuni isolates resistant to ciprofloxacin increased from 12.4% in 1997 to 21.5% in 2005 
(Table 5.06); this increase was statistically significant (OR=2.2, 95% CI [1.4, 3.5]).  Erythromycin resistance was 
low at 1.9% or less during 1997 to 2005. 
 
The percentage of resistance to most agents tested, including ciprofloxacin and erythromycin, was higher in C. 
coli compared with C. jejuni.  In 2005, the highest levels of resistance among the 98 C. coli isolates were to 
tetracycline (30.6%), nalidixic acid (26.5%), and ciprofloxacin (23.5%) (Table 5.07). The percentage of C. coli 
isolates resistant to ciprofloxacin was 33.3% in 1997, not detected in 1998, but ranged from 12.0% to 47.1% from 
1999 to 2005; it was 23.5% in 2005 (Table 5.08). Resistance to erythromycin was not detected in 1997, 12.5% in 
1998, ranged from 4.0% to 10.0% during 1999 to 2003, decreased to 0.0% in 2004, and increased to 3.1% in 
2005. 
 
Table 5.01: Frequency of Campylobacter species isolated in NARMS, 2005 
 
N (%)
Campylobacter jejuni 791 (88.9%)







Table 5.02: Minimum inhibition concentrations (MICs) and resistance of Campylobacter isolates to 
antimicrobial agents, 2005 (N=890) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin   0.0   0.6 [0.2–1.4] 6.4 34.7 52.6 5.2 0.6 0.1 0.1 0.4
Ketolide Telithromycin   0.7   0.8 [0.3–1.7] 0.1 0.2 0.4 1.2 11.2 39.6 28.3 13.8 3.6 0.7 0.8
Azithromycin   0.1   1.9 [1.1–3.0] 4.4 24.8 43.5 19.3 4.9 0.1 0.9 0.1 0.3 0.1 1.5
Erythromycin   0.0   1.8 [1.0–2.9] 0.6 8.1 34.0 32.8 17.9 3.5 1.2 0.1 0.2 1.6
Ciprofloxacin   0.0  21.7 [19.0–24.5] 0.6 3.1 34.7 30.0 7.2 2.4 0.3 1.9 9.6 5.5 2.6 1.9 0.2
Nalidixic Acid   0.7  22.4 [19.7–25.2] 52.6 20.0 4.4 0.7 3.3 19.1
Phenicols Florfenicol¶ N/A   0.5 [0.2–1.3] 0.2 19.4 61.5 13.4 4.9 0.3 0.2
Tetracyclines Tetracycline   0.8  40.6 [37.3–43.9] 6.5 24.7 16.0 6.5 3.8 0.7 0.4 0.8 0.7 4.2 12.7 23.0
Lincosamides Clindamycin   0.4   1.5 [0.8–2.5] 4.9 27.2 36.3 21.0 5.4 2.7 0.6 0.4 0.3 0.3 0.8
*Percent of isolates with intermediate susceptibility
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest tested concentrations. 
Numbers listed for the lowest tested concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints
were used when available.
¶CLSI guidelines do not currently define a resistance-breakpoint for florfenicol.
§The unshaded areas indicate the range of dilutions tested for each antimicrobial agent. Single vertical bars indicate the breakpoints for susceptibility, while double vertical  


























Table 5.03: Percentage and number of Campylobacter isolates resistant to antimicrobial agents, 1997–2005 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005




Aminoglycosides Gentamicin Not 0.3% 0.0% 0.3% 0.0% 0.0% 0.3% 0.3% 0.7%
(MIC ≥ 8) Tested 1 0 1 0 0 1 1 6
Ketolides Telithromycin Not Not Not Not Not Not Not Not 1.0%
(MIC ≥ 16) Tested Tested Tested Tested Tested Tested Tested Tested 9
Macrolides Azithromycin Not 0.6% 2.2% 1.9% 2.1% 2.0% 0.9% 0.6% 1.9%
(MIC ≥ 8) Tested 2 7 6 8 7 3 2 17
Erythromycin 1.8% 1.0% 1.9% 1.2% 2.1% 1.4% 0.9% 0.3% 1.8%
(MIC ≥ 32) 4 3 6 4 8 5 3 1 16
Quinolones Ciprofloxacin 12.9% 13.9% 18.3% 14.8% 19.5% 20.1% 17.7% 19.0% 21.7%
(MIC ≥ 4) 28 43 58 48 75 71 58 66 193
Nalidixic acid 14.3% 16.8% 21.1% 16.7% 20.3% 20.6% 18.9% 19.6% 22.4%
(MIC ≥ 64) 31 52 67 54 78 73 62 68 199
Phenicols Chloramphenicol 5.1% 2.9% 0.6% 0.0% 0.3% 0.3% 0.0% 1.4% Not
(MIC ≥ 32) 11 9 2 0 1 1 0 5 Teste
Florfenicol* Not Not Not Not Not Not Not Not 0.6%
Susceptible breakpoint: (MIC ≤ 4) Tested Tested Tested Tested Tested Tested Tested Tested 5
Tetracyclines Tetracycline 47.9% 45.5% 43.8% 38.3% 40.9% 41.2% 38.4% 46.1% 40.6%
(MIC ≥ 16) 104 141 139 124 157 146 126 160 361
Lincosamides Clindamycin 1.8% 1.3% 1.3% 0.9% 2.1% 2.0% 0.6% 2.0% 1.5%
(MIC ≥ 8) 4 4 4 3 8 7 2 7 13






Table 5.04: Resistance patterns of Campylobacter isolates, 2005 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005
Total Isolates 217 310 317 324 384 354 328 347 890
% % % % % % % % %
n n n n n n n n n
No resistance detected 47.0% 45.2% 47.3% 52.2% 49.2% 48.3% 50.9% 46.1% 48.4%
 102 140 150 169 189 171 167 160 431
Resistance ≥1CLSI subclass* 53.0% 54.8% 52.7% 47.8% 50.8% 51.7% 49.1% 53.9% 51.6%
 115 170 167 155 195 183 161 187 459
Resistance ≥2 CLSI subclasses* 15.7% 9.7% 13.6% 8.0% 13.3% 12.7% 8.5% 14.1% 13.6%
 34 30 43 26 51 45 28 49 121
Resistance ≥3 CLSI subclasses* 1.8% 2.6% 1.6% 0.9% 1.6% 1.1% 0.9% 1.2% 1.5%
 4 8 5 3 6 4 3 4 13
Resistance ≥4 CLSI subclasses* 0.5% 0.3% 0.9% 0.3% 0.3% 0.0% 0.3% 0.3% 0.3%
 1 1 3 1 1 0 1 1 3
Resistance ≥5 CLSI subclasses* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
 0 0 0 0 0 0 0 0 0
*CLSI: Clinical and Laboratory Standards Institute  
 
Table 5.05: Minimum inhibitory concentrations (MICs) and resistance of Campylobacter jejuni isolates to 
antimicrobial agents, 2005, (N=791) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin   0.0   0.5 [0.1–1.3] 7.1 37.3 51.3 3.3 0.5 0.1 0.4
Ketolide Telithromycin   0.4   0.5 [0.1–1.3] 0.3 0.4 1.3 11.2 41.1 30.0 12.9 1.8 0.4 0.5
Azithromycin   0.1   1.8 [1.0–3.0] 4.8 26.4 46.6 16.9 2.3 1.0 0.1 0.4 0.1 1.3
Erythromycin   0.0   1.6 [0.9–2.8] 0.5 8.7 36.9 33.6 16.2 2.0 0.3 0.1 0.3 1.4
Ciprofloxacin   0.0  21.5 [18.7–24.5] 0.6 3.4 35.9 30.2 5.8 2.3 0.3 1.8 9.5 5.4 2.7 2.0 0.1
Nalidixic Acid   0.8  21.9 [19.0–24.9] 55.0 18.8 3.5 0.8 2.9 19.0
Phenicols Florfenicol¶ N/A   0.5 [0.1–1.3] 0.3 20.7 62.3 12.0 4.2 0.25 0.25
Tetracyclines Tetracycline   0.9  41.8 [38.4–45.4] 7.1 25.0 14.8 5.6 3.7 0.6 0.5 0.9 0.8 4.6 13.5 23.0
Lincosamides Clindamycin   0.5   1.1 [0.5–2.1] 5.2 29.6 38.4 19.6 3.8 1.5 0.3 0.5 0.3 0.9
*Percent of isolates with intermediate susceptibility
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest tested concentrations. 
Numbers listed for the lowest tested concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints
were used when available.
¶CLSI guidelines do not currently define a resistance-breakpoint for florfenicol.
§The unshaded areas indicate the range of dilutions tested for each antimicrobial agent. Single vertical bars indicate the breakpoints for susceptibility, while double vertical  




























Table 5.06: Percentage and number of Campylobacter jejuni isolates resistant to antimicrobial agents, 
1997–2005 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005




Aminoglycosides Gentamicin Not 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.3% 0.5%
(MIC ≥ 8) Tested 1 0 0 0 0 0 1 4
Ketolides Telithromycin Not Not Not Not Not Not Not Not 0.0%
(MIC ≥ 16) Tested Tested Tested Tested Tested Tested Tested Tested 0
Macrolides Azithromycin Not 0.3% 1.7% 1.6% 1.9% 1.8% 0.3% 0.6% 1.8%
(MIC ≥ 8) Tested 1 5 5 7 6 1 2 14
Erythromycin 1.4% 0.7% 1.4% 1.0% 1.9% 1.2% 0.3% 0.3% 1.6%
(MIC ≥ 32) 3 2 4 3 7 4 1 1 13
Quinolones Ciprofloxacin 12.4% 13.8% 17.7% 14.7% 18.4% 20.7% 17.2% 18.1% 21.5%
(MIC ≥ 4) 26 41 52 45 67 68 52 58 170
Nalidixic acid 13.4% 15.5% 20.1% 16.0% 18.9% 21.3% 17.8% 18.4% 21.9%
(MIC ≥ 64) 28 46 59 49 69 70 54 59 173
Phenicols Chloramphenicol 3.8% 1.0% 0.7% 0.0% 0.3% 0.3% 0.0% 1.6% Not
(MIC ≥ 32) 8 3 2 0 1 1 0 5 Teste
Florfenicol* Not Not Not Not Not Not Not Not 0.5%
Susceptible breakpoint: (MIC ≤ 4) Tested Tested Tested Tested Tested Tested Tested Tested 4
Tetracyclines Tetracycline 47.8% 46.1% 45.4% 39.2% 40.3% 41.3% 38.3% 46.9% 41.8%
(MIC ≥ 16) 100 137 133 120 147 136 116 150 331
Lincosamides Clindamycin 1.0% 1.0% 0.7% 0.7% 1.9% 1.8% 0.0% 2.2% 1.1%
(MIC ≥ 8) 2 3 2 2 7 6 0 7 9





Table 5.07: Minimum inhibitory concentrations (MICs) and resistance of Campylobacter coli isolates to 
antimicrobial agents, 2005 (N=98) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Aminoglycosides Gentamicin   0.0   1.1 [0.0–5.8] 1.1 12.8 63.8 20.2 1.1 1.1
Ketolide Telithromycin   3.2   3.2 [0.7–9.0] 1.1 11.7 26.6 14.9 21.3 18.1 3.2 3.2
Azithromycin   0.0   3.1 [0.6–8.7] 1.0 11.2 18.4 38.8 26.5 1.0 3.1
Erythromycin   0.0   3.1 [0.6–8.7] 1.0 3.1 11.2 25.5 31.6 15.3 9.2 3.1
Ciprofloxacin   0.0  23.5 [15.5–33.1] 1.0 25.5 27.6 18.4 3.1 1.0 3.1 10.2 6.1 2.0 1.0 1.0
Nalidixic Acid   0.0  26.5 [18.1–36.4] 32.7 29.6 11.2 6.1 20.4
Phenicols Florfenicol¶ N/A   1.0 [0.0–5.6] 9.2 54.1 24.5 11.2 1.0
Tetracyclines Tetracycline   0.0  30.6 [21.7–40.7] 2.0 21.4 25.5 14.3 5.1 1.0 1.0 6.1 23.5
Lincosamides Clindamycin   0.0   4.1 [1.1–10.1] 3.1 8.2 19.4 31.6 18.4 12.2 3.1 3.1 1.0
*Percent of isolates with intermediate susceptibility
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
bars indicate breakpoints for resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest tested concentrations. 
Numbers listed for the lowest tested concentrations represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints
were used when available.
¶CLSI guidelines do not currently define a resistance-breakpoint for florfenicol.
§The unshaded areas indicate the range of dilutions tested for each antimicrobial agent. Single vertical bars indicate the breakpoints for susceptibility, while double vertical  



























Table 5.08: Percentage and number of Campylobacter coli isolates resistant to antimicrobial agents, 1997–
2005 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005




Aminoglycosides Gentamicin Not 0.0% 0.0% 8.3% 0.0% 0.0% 4.5% 0.0% 2.0%
(MIC ≥ 8) Tested 0 0 1 0 0 1 0 2
Ketolides Telithromycin Not Not Not Not Not Not Not Not 4.1%
(MIC ≥ 16) Tested Tested Tested Tested Tested Tested Tested Tested 4
Macrolides Azithromycin Not 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0% 3.1%
(MIC ≥ 8) Tested 1 2 1 1 1 2 0 3
Erythromycin 0.0% 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0% 3.1%
(MIC ≥ 32) 0 1 2 1 1 1 2 0 3
Quinolones Ciprofloxacin 33.3% 0.0% 30.0% 25.0% 47.1% 12.0% 22.7% 30.8% 23.5%
(MIC ≥ 4) 2 0 6 3 8 3 5 8 23
Nalidixic acid 50.0% 50.0% 30.0% 25.0% 47.1% 12.0% 22.7% 34.6% 26.5%
(MIC ≥ 64) 3 4 6 3 8 3 5 9 26
Phenicols Chloramphenicol 50.0% 37.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Not
(MIC ≥ 32) 3 3 0 0 0 0 0 0 Teste
Florfenicol* Not Not Not Not Not Not Not Not 1.0%
Susceptible breakpoint: (MIC ≤ 4) Tested Tested Tested Tested Tested Tested Tested Tested 1
Tetracyclines Tetracycline 66.7% 50.0% 30.0% 25.0% 58.8% 40.0% 45.5% 38.5% 30.6%
(MIC ≥ 16) 4 4 6 3 10 10 10 10 30
Lincosamides Clindamycin 16.7% 12.5% 10.0% 8.3% 5.9% 4.0% 9.1% 0.0% 4.1%
(MIC ≥ 8) 1 1 2 1 1 1 2 0 4





Limitations to NARMS Campylobacter Surveillance 
 
Three limitations are evident in NARMS Campylobacter surveillance; the use of sentinel clinical laboratories in 
some states, the sampling scheme implemented during 1997 to 2004, and the limited geographic area under 
surveillance. 
 
In four states that participated in NARMS Campylobacter surveillance (California, Colorado, Connecticut, and 
Oregon), Campylobacter isolates were submitted to NARMS from one sentinel clinical laboratory. In Georgia, 
Maryland, Minnesota, New Mexico, New York, and Tennessee, the Campylobacter isolates submitted were 
selected from all Campylobacter isolates from most clinical laboratories within a specific geographic area (metro 
Atlanta area in Georgia; statewide in Maryland, Minnesota, New Mexico, and Tennessee; and the metro Albany 
and Rochester areas in New York). In California, Colorado, Connecticut, and Oregon from 1997 to 2004, the 
sentinel clinical laboratory selected the first Campylobacter isolate isolated each week for submission to NARMS; 
if no isolate was isolated in a week, then no isolate was submitted from that laboratory. From the other six 
FoodNet sites, one Campylobacter isolate among isolates received from participating clinical laboratories was 
also selected each week.  Because none of the sentinel clinical laboratories used an isolation procedure that was 
more or less likely than the procedure of other clinical laboratories in their respective states to yield antimicrobial-
resistant Campylobacter isolates, use of a sentinel clinical laboratory was unlikely to be associated with a change 
of antimicrobial resistance among Campylobacter isolates submitted to NARMS. 
 
From 1997 to 2004, the NARMS participating public health laboratories in Georgia, Maryland, Minnesota, New 
Mexico, New York, and Tennessee, and sentinel clinical laboratories in all other FoodNet sites selected one 
Campylobacter isolate each week and forwarded the isolate to CDC. When the isolates were selected, the 
antimicrobial resistance pattern of the isolates was not known. Therefore, the antimicrobial resistance pattern of 
an isolate was unlikely to influence submission of the isolate to NARMS. However, the one-a-week sampling 
scheme could have resulted in oversampling or undersampling of antimicrobial-resistant isolates if the prevalence 
of such resistance was not uniform throughout the year. The impact of oversampling or undersampling can vary 
among states.  In 2005, a representative sampling scheme was initiated in the 10 FoodNet sites. 
 
Campylobacter isolates were forwarded to CDC by 10 states participating in FoodNet during 2005, representing 
approximately 45 million persons (15% of the U.S. population). Because NARMS 2005 Campylobacter surveillance 
was not nationwide, findings should be generalized to the U.S. population with caution because of possible 









1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility 
Testing; Eighteenth Informational Supplement. CLSI Document M100-S18. Clinical and Laboratory Standards 
Institute, Wayne, Pennsylvania, 2008. 
2. Linton D, Lawson AJ, Owen RJ, Stanley J. PCR detection, identification to species level, and fingerprinting of 
Campylobacter jejuni and Campylobacter coli direct from diarrheic samples. Journal of Clinical Microbiology 
1997;35:2568–72. 
3. Gonzalez I, Grant KA, Richardson PT, Park SF, Collins MD. Specific identification of the enteropathogens 
Campylobacter jejuni and Campylobacter coli by using a PCR test based on the ceuE gene encoding a 
putative virulence determinant. Journal of Clinical Microbiology 1997;35:759–63. 
4. Linton D, Owen RJ, Stanley J. Rapid Indentification by PCR of the genus Campylobacter and of five 
Campylobacter species enteropathogenic for man and animals. Research in Microbiology 1996;147:707-718. 
5. CDC. National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): 2004 Human 
Isolates Final Report. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2007. 
6. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing 
of Infrequently Isolated or Fastidious Bacteria: Approved Guideline. CLSI Document M45-A. Clinical and 
Laboratory Standards Institute, Wayne, Pennsylvania, 2006. 
7. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. 
Statistics in Medicine 1998;17:857-872.  
8. Fleiss JL, Levin B, Paik MC. Statistical Methods in for Rates and Proportions. In: Shewart WA, Wilks SS, eds. 





NARMS Publications in 2005 
 
1. Anderson AD, Nelson JM, Baker NL, S R, and Angulo FJ. Public health consequences of use of antimicrobial 
agents in agriculture. In: Smulders JM, Collins JD, editors. Food Safety Assurance and Veterinary Public 
Health Vol 3: Risk Management Strategies: Monitoring and Surveillance. The Netherlands: Wageningen 
Academic Publishers; 2005. p. 173-84. 
2. Devasia RA, Varma JK, Whichard J, Gettner S, Cronquist AB, Hurd S, Segler S, Smith K, Hoefer D, Shiferaw 
B, Angulo FJ, and Jones TF. Antimicrobial use and outcomes in patients with multidrug-resistant and 
pansusceptible Salmonella Newport infections, 2002-2003. Microbial Drug Resistance 2005;11(4):371-7. 
3. Fisk TL, Lundberg BE, Guest JL, Ray S, Barrett TJ, Holland B, Stamey K, Angulo FJ, and Farley MM.  
Invasive infection with multidrug-resistant Salmonella enterica serotype Typhimurium definitive type 104 
among HIV-infected adults. Clinical Infectious Diseases 2005;40(7):1016-21. 
4. Gupta A, Tauxe RV, and Angulo FJ. Fluoroquinolone use in food animals [response]. . Emerging Infectious 
Diseases 2005;11(11):1791-2. 
5. Hannah EL, Angulo FJ, Johnson JR, Haddadin B, Williamson J, and Samore MH. Drug-resistant Escherichia 
coli, rural Idaho. Emerging Infectious Diseases 2005;11(10):1614-7. 
6. Nelson JM, Tauxe RV, and Angulo FJ. Correspondence: Ciprofloxacin resistance does not affect duration of 
domestically acquired campylobacteriosis. The Journal of Infectious Diseases 2005;11(9):1565-6. 
7. Rankin SC, Whichard JM, Joyce K, Stephens L, O'Shea K, Aceto H, Munro DS, and Benson CE. Detection of 
a blaSHV extended-spectrum β-lactamase in Salmonella enterica serovar Newport MDR-AmpC. Journal of 
Clinical Microbiology 2005;43(11):5792-3. 
8. Varma JK, Mølbak K, Jones TF, Smith KE, Vugia DJ, Barrett TJ, Rabatsky-Ehr T, and Angulo FJ. Reply to 
Cox and Phillips: Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream 
infections and hospitalizations. The Journal of Infectious Diseases 2005;192(11):2030-1. 
9. Varma JK, Greene KD, Ovitt J, Barrett TJ, Medalla F, and Angulo FJ. Hospitalization and antimicrobial 
resistance in Salmonella outbreaks, 1984-2002. Emerging Infectious Diseases 2005;11(6):943-6. 
10. Varma JK, Molbak K, Barrett TJ, Beebe JL, Jones TF, Rabatsky-Ehr T, Smith KE, Vugia DJ, Chang HG, and 
Angulo FJ.  Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections 
and hospitalizations. The Journal of Infectious Diseases 2005;191(4):554-61. 
11. Whichard JM, Joyce K, Fey PD, Nelson JM, Angulo FJ, and Barrett TJ. Beta-lactam resistance and 
Enterobacteriaceae, United States. Emerging Infectious Diseases 2005;11(9):1464-6. 
12. Wright JG, Tengelsen LA, Smith KE, Bender JB, Frank RK, Grendon JH, Rice DH, Thiessen AM, Gilbertson 
CJ, Sivapalasingam S, Barrett TJ, Besser TE, Hancock DD, and Angulo FJ. Multidrug-resistant Salmonella 



























NARMS Abstracts & Invited Lectures in 2005 
 
 
1.  Burger KL, Black RL, Whichard JM, Sivapalasingam S, and Barrett TJ. Ampicillin and trimethoprim-
sulfamethoxazole resistance mechanisms among Shigella species: results of NARMS monitoring, 2002. ASM 
Southeastern Branch Meeting, St. Petersburg, FL, October 2005. 
2.  Chatman T, Holzbauer S, Averill J, Bartlett P, Bair H, Bernardo T, Malinowski R, Tu L, and Chiller T. 
Appropriate use of antimicrobial agents in veterinary medicine: an educational program.   3rd National 
Prevention Summit: Innovations in Community Prevention, Washington, D.C., October 2005. 
3.  Chiller T. Broadening your appropriate use program to agriculture; current data, trends, and importance of 
monitoring pathogens of public health concern.  CDC’s Conference on Antimicrobial Resistance Programs 
Building Bridges: Surveillance, Atlanta, GA, April 2005 (invited lecture). 
4.  Chiller T. Foodborne disease surveillance and antibiotic resistance. Pennsylvania Public Health Institute, State 
College, PA, May 2005 (invited lecture). 
5.  Chiller T. Household treatment of drinking water and hygiene reduce disease in developing country 
households. ASM Symposium on Drinking Water Treatment and Safe Storage for Households in Developing 
Countries, June 2005 (invited lecture). 
6.  Chiller T. Human NARMS surveillance.  Public Health Agency for Canada’s International Network on 
Integrated Surveillance of Antimicrobial Resistance Conference, Winnipeg, Canada, September 2005 (invited 
lecture). 
7.  Chiller T, May A, Lewis K, Gay K, Barrett T, and the NARMS Enterococci Working Group. Community 
associated vancomycin-resistant enterococci (VRE) from human stools in the United States.  2nd International 
ASM-FEMS Conference on Enterococci, Helsingor, Denmark, August 2005. 
8.   Chiller T, May A, Lewis K, Gay K, Barrett T and the NARMS Enterococci Working Group.  Vancomycin-
resistant enterococci (VRE) carriage in the community: is this a new reservoir for infection?  Proceedings of 
the 43rd Meeting, Infectious Diseases Society of America, San Francisco, CA, October 2005. 
9.  Dunn J, Saketa S, Pryor J, Delai W, Buadromo E, Kishore K, Sanjappa S, Singh S, Iddings S, and Chiller T. 
Laboratory-based Salmonella surveillance in Fiji: a model for foodborne disease surveillance in Pacific Island 
Countries.  3rd Pacific Global Health Conference, Hawaii, June 2005. 
10.  Gay K, May A, Lewis K, Barrett T, Chiller T, and the NARMS Enterococci Working Group.  Carriage of 
quinupristin-dalfopristin-resistant Enterococcus faecium, including high level MICs, in human stools and 
grocery store meats in the US.  2nd International ASM-FEMS Conference on Enterococci, Helsingor, 
Denmark, August 2005. 
11.  Gupta S, Whichard J, Medalla F, Chiller T, and Mintz E.  Salmonella Paratyphi A in the United States: travel 
and quinolone resistance.  The 54th American Society of Tropical Medicine and Hygiene Annual Meeting, 
Washington, D.C., December 2005. 
12.  Holzbauer S, Averill J, Bartlett P, Bair H, Bernardo T, Malinowski R, Tu L, and Chiller T. Appropriate use of 
antimicrobial agents in veterinary medicine:  an educational program.  Agriculture's Role in Managing 
Antimicrobial Resistance the Road to Prudent Use Conference 2005, Toronto, Ontario, October 2005. 
13.  Lyszkowicz E, Gay K, Joyce KJ, Medalla F, Ahmed R, Whichard J, Chiller T, and Barrett T. Phage types of 
nalidixic acid resistant Salmonella Enteritidis in the U.S. from 1996 to 2003.  Proceedings of the 43rd Meeting, 
Infectious Diseases Society of America, San Francisco, CA, October 2005. 
14.  May A, Lewis K, Gay K, Barrett T, Chiller T, and the NARMS Enterococci Working Group. Vancomycin-
resistant enterococci (VRE) from human stools in the community.  2005 National Foundation of Infectious 
Diseases Annual Conference on Antimicrobial Resistance, Bethesda, MD, June 2005. 
15.  Medalla F, Gay K, Smith J, Barrett T, Chiller T, and the NARMS Working Group.  Antimicrobial resistance in 
Campylobacter, NARMS 1997-2003.  45th Interscience Conference on Antimicrobial Agents and 
Chemotherapy, Washington, D.C., December 2005.  
16.  Medalla F, Gay K, Barrett T, Chiller T, and the NARMS Working Group.  Nalidixic acid-resistance in 
Salmonella Enteritidis, NARMS, 1996-2003.  2005 National Foundation of Infectious Diseases Annual 
Conference on Antimicrobial Resistance, Bethesda, MD, June 2005. 
17.  Stancik L, Barrett T, Braden C, and Chiller T.  Outbreaks caused by drug-resistant versus pan-susceptible 
non-Typhi Salmonella: NARMS, 1996-2004. Proceedings of the 43rd Meeting, Infectious Diseases Society of 
America, San Francisco, CA, October 2005. 
18.  Whichard JM. Surveillance of antimicrobial resistance among Salmonella, Shigella and E. coli O157 in the 
U.S., and other molecular pursuits with Enterobacteriaceae at CDC.  Virginia Tech Molecular Cell Biology and 
Biotechnology Seminar series. Virginia Tech, Blacksburg, VA, October 2005 (invited lecture). 
68 
19.  Whichard JM. Human NARMS isolates in the U.S.: Salmonella Enteritidis phage type results. International 
Federation of Enteric Phage Typing, International Union of Microbiological Societies, San Francisco, CA, July 
2005. 
 
20.  White D, Carter P, Cullen P, Hall-Robinson E, Hubert S, Ayers S, McDermott S, Walker A, Proescholdt T, 
Walker R, Chiller T, McDermott P, and the NARMS Working Group.  Antimicrobial resistance among 
Enterococcus spp. recovered from retail foods of animal origin, NARMS 2003.  2nd International ASM-FEMS 
Conference on Enterococci, Helsingor, Denmark, August 2005. 
  
APPENDIX A 






Frederick Angulo, Tim Barrett, Ezra Barzilay, Tom Chiller, Kathryn Gay, Patricia Griffin, Amy Krueger, 
 Katie Joyce, Kevin Joyce, Amie ThurdeKoos, Terrell Miller, Felicita Medalla, Robert Tauxe 
Foodborne and Diarrheal Diseases Branch, Division of Bacterial and Mycotic Diseases 
National Center for Infectious Diseases 
 
Participating State and Local Health Departments 
 
Maryland Department of Health and Mental Hygiene and University of Maryland  
Karen Cuenco, Jonigene Ruark, David Torpey, Mary Warren  
 
Michigan Department of Community Health and William Beaumont Hospital 
Sue Donabedian, Mary Beth Perry, Mary Thill, Mark Zervos 
 
Centers for Disease Control and Prevention 




Escherichia coli is a gram-negative rod that is part of the intestinal flora of humans and other animals. Because 
antimicrobial resistance genes commonly reside in mobile genetic elements that can be transferred horizontally to 
other bacteria, antimicrobial-resistant bacteria of the intestinal flora, including E. coli, constitute an important 
reservoir of resistance genes for pathogenic bacteria of humans and other animals. Furthermore, when 
introduced into a normally sterile site, E. coli is an important cause of infections, including septicemia, urinary tract 
infections, and wound infections. The human intestinal tract is the predominant source of E. coli causing these 
infections. Antimicrobial resistance among E. coli causing such infections complicates treatment options. 
 
The use of antimicrobial agents creates a selective pressure for the emergence and dissemination of resistant 
bacteria. Use of antimicrobial agents in food animals selects resistant bacteria, including resistant E. coli in the 
intestinal tract of food animals. These resistant bacteria can be transmitted to humans through the food supply1,2,3. 
Therefore, monitoring resistance in E. coli isolated from the intestinal flora of humans and animals is important to 
determining the role of these bacteria as human pathogens and as reservoirs of resistance determinants for 
human pathogens4. The E. coli Resistance Surveillance Pilot is designed to determine the prevalence of 
resistance to clinically important antimicrobial agents among E. coli isolated from persons in the community. 
 




Beginning in 2004, NARMS began to prospectively monitor the prevalence of antimicrobial resistance of E. coli 
isolated from human stool samples in two sites: Maryland and Michigan. 
 
Multidrug-Resistant E. coli 
 
• 25.4% of 118 E. coli isolates tested were resistant to two or more subclasses of antimicrobial agents. 




Clinically Important Resistance 
 
Antimicrobial agents commonly used to treat serious E. coli infections in humans include third-generation 
cephalosporins and fluoroquinolones. 
• 0.8% of 118 E. coli isolates were resistant to ceftiofur (Table A.04). 
• 7.6% of 118 E. coli isolates were resistant to ciprofloxacin (Table A.04). 
 
SURVEILLANCE AND LABORATORY TESTING METHODS 
 
Participating laboratories in Maryland and Michigan cultured 10 human stool samples each month for E. coli using 
Eosin Methylene Blue agar one E. coli isolate, if present, from each stool sample was sent to CDC for 
susceptibility testing to antimicrobial agents using broth microdilution (Sensititre®) to determine the minimum 
inhibitory concentration (MIC) for each of 15 antimicrobial agents: amikacin, ampicillin, amoxicillin-clavulanic acid, 
cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, 
streptomycin, sulfamethoxazole, tetracycline, and trimethoprim-sulfamethoxazole (Table A.01). The resistance 
breakpoint for amikacin, according to CLSI5 guidelines, is an MIC of 64 µg/mL. 
 
Interpretive criteria from the Clinical Laboratory and Standards Institute (CLSI) were used (Table A.01). The 95% 
CIs for the percentage of resistant isolates calculated using the Clopper-Pearson exact method, are included in 
the MIC distribution tables. Similarly, multiclass resistance by CLSI antimicrobial subclass was defined as 




In 2005, CDC received and tested 118 viable E. coli isolates (Table A.02). Minimum Inhibitory Concentrations 
(MIC) was determined for E. coli isolates for 15 antimicrobial agents (Table A.03). 
 
Of the E. coli isolates, 26.3% were resistant to ampicillin; 19.5% to tetracycline; 17.7%, to sulfamethoxazole; and 
9.3% to nalidixic acid (Table A.04). 
 
In 2005, 22.9% of E. coli isolates were resistant to two or more CLSI subclasses, and 7.6% were resistant to five 
or more CLSI subclasses (Table A.05). The level of E. coli resistance in this pilot study differs than that observed 
in NARMS 2004. Because of the different sampling methods between this study and NARMS, this observation 
requires further investigation. 
 
There is a difference in the level of resistance among E. coli isolates in this study compared with E. coli O157 
isolates submitted to NARMS in 2005. Because of the different sampling methods employed between this study 
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Table A.01: Antimicrobial agents used for susceptibility testing of Escherichia coli, 2005 
Susceptible Intermediate Resistant
Amikacin* 0.5 – 4* ≤16 32 ≥64
Gentamicin 0.25 – 16 ≤4 8 ≥16
Kanamycin 8 – 64 ≤16 32 ≥64
Streptomycin 32 – 64 ≤32  ≥64
Aminopenicillins Ampicillin 1 – 32 ≤8 16 ≥32
β-lactamase inhibitor combinations Amoxicillin–Clavulanic acid 1/0.5 – 32/16 ≤8/4 46/8 ≥32/16
Ceftiofur 0.12– 8 ≤2 4 ≥8
Ceftriaxone 0.25 – 64 ≤8 16-32 ≥64
Cephamycins Cefoxitin 0.5 – 16 ≤8 16 ≥32
Folate pathway inhibitors Trimethoprim–Sulfamethoxazole 0.12/2.4 – 4/76 ≤2/38 ≥4/76
Phenicols Chloramphenicol 2 – 32 ≤8 16 ≥32
Ciprofloxacin 0.015 – 4 ≤1 2 ≥4
Nalidixic acid 0.5 – 32 ≤16 ≥32
Sulfonamides Sulfisoxazole 16 – 512 ≤256 ≥512
Tetracyclines Tetracycline 4 – 16 ≤4 8 ≥16
Breakpoints
* The resistance breakpoint for amikacin, according to Clinical and Laboratory Standards Institute (CLSI) guidelines, is 64µg/mL.  For isolates that 
grew in all amikacin dilutions on the Sensititre panel (minimum inhibitory concentration [MIC] >4 µg/mL), E-Test (AB BIODISK, Solna, Sweden) 
was performed in order to determine amikacin MIC.  The amikacin E-Test strip range of dilutions is 0.016-256 µg/mL.









Table A.02: Escherichia coli isolates received and tested at CDC, by site, 2005 









Table A.03: Minimum inhibition concentrations (MICs) of Escherichia coli, 2005 (N=118) 
%I* %R† [95% CI]‡ 0.015 0.03 0.06 0.125 0.25 0.50 1 2 4 8 16 32 64 128 256 512
Amikacin 0.0 0.0 [0.0–2.6] 0.8 44.1 50.8 4.2
Gentamicin 0.0 3.3 [2.2–8.3] 17.8 70.3 8.5 0.8 2.5
Streptomycin NA 14.4 [9.6–19.2] 85.6 5.9 8.5
Aminopenicillins Ampicillin 2.5 26.3 [24.1–36.7] 7.6 44.1 16.9 2.5 2.5 26.3
β-lactamase 
inhibitor Amoxicillin-clavulanic acid 3.4 4.2 [1.6–7.2] 4.2 19.5 46.6 22.0 3.4 3.4 0.8
Ceftiofur 0.8 0.8 [0.0–2.6] 8.5 57.6 31.4 0.8 0.8 0.8
Ceftriaxone 0.8 0.0 [0.0–2.6] 98.3 0.8 0.8
Ciprofloxacin 0.0 7.6 [5.7–13.9] 90.7 1.7 7.6
Nalidixic Acid NA 9.3 [14.0–24.9] 22.9 61.0 6.8 9.3
Aminoglycosides Kanamycin 0.0 0.0 [0.8–5.3] 98.3 1.7
Cephamycins Cefoxitin 1.7 0.8 [1.3–6.6] 5.1 50.0 33.9 8.5 1.7 0.8
Folate pathway 
inhibitors Trimethoprim-sulfamethoxazole NA 14.2 [11.2–21.3] 76.1 8.8 0.9 14.2
Phenicols Chloramphenicol 0.8 2.5 [0.5–4.7] 4.2 66.1 26.3 0.8 2.5
Sulfonamides Sulfamethoxazole/Sulfisoxazole NA 17.7 [17.7–29.4] 73.5 8.8 17.7
Tetracyclines Tetracycline 1.7 19.5 [12.4–22.8] 78.8 1.7 5.1 14.4
*Percent of isolates with intermediate susceptibility, NA if no MIC range of intermediate susceptibility exists
†Percent of isolates that were resistant
‡95% confidence intervals (CI) for percent resistant (%R) were calculated using the Clopper-Pearson exact method
§The unshaded areas indicate the dilution range of the Sensititre plates used to test isolates. Single vertical bars indicate the breakpoints for susceptibility, while double vertical bars indicate breakpoints for 
resistance. Numbers in the shaded areas indicate the percentages of isolates with MICs greater than the highest concentrations on the Sensititre plate. Numbers listed for the lowest tested concentrations 
represent the precentages of isolates with MICs equal to or less than the lowest tested concentration. CLSI breakpoints were used when available.
% of isolates Percent of all isolates with MIC (µg/mL)§
Aminoglycosides





























Table A.04: Escherichia coli isolates with antimicrobial resistance, 2005 
Year 2004 2005





(MIC ≥ 64) 0 0
Gentamicin 2.0% 3.4%
(MIC ≥ 16) 3 4
Streptomycin 10.6% 14.4%
(MIC ≥ 64) 16 17
Ampicillin 24.5% 26.3%
(MIC ≥ 32) 37 31
Amoxicillin-clavulanic acid 2.6% 4.2%
(MIC ≥ 32) 4 5
Ceftiofur 0.0% 0.8%
(MIC ≥ 8) 0 1
Ceftriaxone 0.0% 0.0%
(MIC ≥ 64) 0 0
Ciprofloxacin 3.3% 7.6%
(MIC ≥ 4) 5 9
Nalidixic Acid 9.3% 9.3%
(MIC ≥ 32) 14 11
Aminoglycosides Kanamycin 2.0% 0.0%
(MIC ≥ 64) 3 0
Cefoxitin 2.6% 0.8%
(MIC ≥ 32) 4 1
Trimethoprim-sulfamethoxazole 11.3% 14.2%
(MIC ≥ 4) 17 16
Chloramphenicol 1.3% 2.5%
(MIC ≥ 32) 2 3
Sulfamethoxazole/Sulfisoxazole 17.9% 17.7%
(MIC ≥ 512) 27 20
Tetracycline 13.2% 19.5%
(MIC ≥ 16) 20 23
















Table A.05: Antimicrobial agents resistant to Escherichia coli, 2005 
Year 2004 2005
Total Isolates 151 118
% %
n n
No resistance detected 62.9% 63.6%
 95 75
Resistance ≥1CLSI subclass* 37.7% 36.4%
 57 43
Resistance ≥2 CLSI subclasses* 17.9% 22.9%
 27 27
Resistance ≥3 CLSI subclasses* 9.9% 14.4%
 15 17
Resistance ≥4 CLSI subclasses* 5.3% 9.3%
 8 11
Resistance ≥5 CLSI subclasses* 3.3% 7.6%
 5 9
At least ACSSuT† 1.3% 0.8%
 2 1
At least ACSuTm‡ 1.3% 0.8%
 2 1
At least ACSSuTAuCf§ 0.0% 0.0%
 0 0
At least AAuC¶ 0.0% 0.0%
 0 0
At least A3C** 0.0% 0.0%
 0 0
At least MDR-AmpC†† 0.0% 0.0%
 0 0
Resistance to quinolone and cephalosporin (3rd generation) 0.0% 0.0%
 0 0
*CLSI: Clinical and Laboratory Standards Institute 
†ACSSuT: resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline 
‡ACSuTm: resistance to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole 
§ACSSuTAuCf: resistance to ACSSuT + amoxicillin-clavulanic acid, ceftiofur 
¶AAuC: resistance to ampicillin, amoxicillin-clavulanic acid, ceftiofur  
**A3C: resistance to amikacin, ampicillin, amoxicillin-clavulanic acid




Among isolates of commensal E. coli ceftiofur resistance has increased from 0.0% in 2004 to 0.8% in 2005.  
Ciprofloxacin resistance increased from 3.3% in 2004 to 7.6% in 2005.  A decrease in detected resistance was 




International Comparison of Antimicrobial MIC-Distributions 
 
 
Several committees determine clinical antimicrobial MIC breakpoints. In the U.S., breakpoints have traditionally 
been determined by the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS) and the FDA. In Europe, 
the ESCMID-formed authority EUCAST (European Committee on Antimicrobial Susceptibility Testing) has been 
tasked with harmonizing clinical breakpoints for existing drugs in Europe and to determine breakpoints for new 
antimicrobial agents as part of the regulatory process for approval of new drugs in Europe [1-3]. In addition to 
clinical breakpoints, EUCAST has introduced the concept of epidemiological cut-off values (ECOFFs) as a way of 
distinguishing bacteria without resistance mechanisms (“wild type”) from those with mutational or acquired 
resistance [1, 4]. The ECOFF is expressed as WT ≤ Xmg/L and will divide the distribution into two groups; those 
that are wild type (WT) and those that are non-wild type (NWT). Thus, ECOFFs do not relate to clinical efficacy - 
instead they were introduced to allow the sensitive measurement and comparison of resistance as a biological 
phenomenon.  
The EUCAST webpage displays MIC wild type-distributions for many organism-drug combinations 
(http://www.eucast.org). An example of a wild type MIC distribution is shown in Figure 1. EUCAST’s wild type 
distributions are based on MIC-data collected from all over the world and from various sources, including humans, 
animals and plants. The typical wild type MIC distribution spans over 3-5 dilution steps. 
In theory, the wild type MIC-distributions should, for a given organism-drug combination, be the same 
irrespective of the origin of the isolates. Below are some examples of how the CDC distributions of Escherichia 
coli compare to the distributions defined by EUCAST (Figure 2). Even though the CDC-distributions do not 
represent full range MIC-distributions (hence leaving one or the other end of the distribution truncated) a good 
correlation between EUCAST and CDC distributions can be observed. This confirms that E. coli wild type 
distributions are similar regardless of origin and source. NARMS is currently participating in international 
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List of Abbreviations 
 
 
ACSSuT Resistance to at least ampicillin, chloramphenicol, streptomycin, 
sulfamethoxazole/sulfisoxazole, and tetracycline 
ACSSuTAuC  Resistance to at least ACSSuT , amoxicillin-clavulanic acid, and ceftiofur 
ACSuTm  Resistance to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole 
CDC   Centers for Disease Control and Prevention 
CI   Confidence interval 
CLSI   Clinical and Laboratory Standards Institute 
EIP   Emerging Infections Program 
ELC   Epidemiology and Laboratory Capacity 
EMB   Eosin methylene blue 
ENTFM   Enterococcus faecium 
ENTFS   Enterococcus faecalis 
ERS   Enterococci Resistance Surveillance 
FDA   Food and Drug Administration 
FoodNet  Foodborne Diseases Active Surveillance Network 
MDR-AmpC Resistance to at least ACSSuT, amoxicillin-clavulanic acid, and ceftiofur, and decreased 
susceptibility to ceftriaxone (MIC ≥ 2 µg/mL) 
MIC   Minimum inhibitory concentration 
NARMS National Antimicrobial Resistance Monitoring System for Enteric Bacteria 
OR  Odds ratio 
PCR  Polymerase chain reaction 
PHLIS  Public Health Laboratory Information System 
VRE   Vancomycin-resistant enterococci 
 
